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Functional characterization of 
peroxisomes in the heart and the role 
of Pex11α and Pex14 in 
cardiomyocytes 
 
1. Introduction 
1.1. The peroxisome and its functions in cellular metabolism 
1.1.1. The history of peroxisomes  
The organelles now known as peroxisomes were discovered by (Rhodin, 1954) and 
were initially named microbodies. Two years later, similar structures, 0.2–1 µm in 
diameter and bound by a single membrane, were also found in rat liver parenchymal 
cells, and featured a characteristic dense core in the matrix with a regular crystalloid 
structure (Bernhard and Rouiller, 1956). Later studies revealed that the crystalloid core, 
which contains urate oxidase, is not present in all cell types, but is found in human and 
rodent liver cells, and in the bovine kidney (Zaar et al., 1987). Twelve years after their 
discovery, microbodies were renamed peroxisomes (De Duve and Baudhuin, 1966). 
Peroxisomes were initially identified by cytochemical staining, exploiting the ability of 
catalase to oxidize 3,3′-diaminobenzidine (DAB) (Fahimi, 1969). This method is still 
widely used to characterize peroxisomes (Fahimi and Baumgart, 1999). However, as 
information about additional peroxisome enzymes has accumulated, other techniques 
have been developed, such as the cerium technique that detects oxidase activity. 
Moreover, immunocytochemical techniques based on peroxisome-specific antibodies 
have been used to study the heterogeneous protein composition of peroxisomal 
compartments, which also enabled detailed functional analysis of the peroxisome in 
different organ systems (Fahimi et al., 1999). 
 
1.1.2. Peroxisome metabolic pathways   
Peroxisomes contain more than 130 different proteins which are involved in a variety 
of metabolic pathways (Karnati and Baumgart-Vogt, 2008). The most important 
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functions are the β-oxidation of very-long-chain fatty acids (VLCFAs) and the 
metabolism of reactive oxygen species (ROS) (Moser et al., 1984). Other metabolic 
pathways include etherphospholipid synthesis, docosahexaenoic acid (DHA) synthesis, 
glyoxylate metabolism, amino acid degradation, and bile acid synthesis (Wanders et 
al., 2016).  
 
1.1.2.1. Peroxisomal β-oxidation of fatty acids  
The peroxisomal fatty acid β-oxidation pathway is found in most of cell types and 
organisms (Waterham et al., 2016). In humans, β-oxidation occurs in both peroxisomes 
and mitochondria (Waterham et al., 2016). Fatty acids with a methyl group at the 3-
position (e.g. phytanic acid) need prior α-oxidation in peroxisomes, which requires the 
enzymes phytanoyl-CoA 2-hydroxylase, 2-hydroxyphytanoyl-coenzyme A (CoA) lyase, 
and pristanal dehydrogenase, before β-oxidation takes place (Waterham et al., 2016). 
The peroxisomes and mitochondria share the principal catalytic mechanism of β-
oxidation, which is the shortening of fatty acid chains by removing two carbons via 
dehydrogenation, hydration, dehydrogenation, and thiolytic cleavage (Waterham et al., 
2016). Different pathways in each organelle produce flavin adenine dinucleotide 
(FAD/FADH2) (Waterham et al., 2016). In peroxisomes, the FADH2 reacts with 
dioxygen (O2) to produce hydrogen peroxide (H2O2), which is degraded by peroxisomal 
catalase into water (H2O) and O2, whereas in mitochondria the re-oxidation of FADH2 
is coupled to the electron transport chain to produce energy (Van Veldhoven, 2010; 
Wanders, 2004; Wanders et al., 2010; Waterham et al., 2016). 
Peroxisomal fatty acid β-oxidation requires an acyl-CoA oxidase (dehydrogenation 
step), a bifunctional enzyme (hydration and dehydrogenation steps), and a thiolase (for 
thiolytic cleavage) (Reddy and Hashimoto, 2001). Unlike mitochondria, which can fully 
oxidize fatty acids to carbon dioxide (CO2) and H2O, peroxisomes can only shorten 
fatty acid chains (C˃8). The end products of peroxisomal β-oxidation must therefore 
be shuttled to the mitochondria (Wanders, 2014). On the other hand, VLCFAs (C>20) 
are exclusively degraded in peroxisomes (Sassa and Kihara, 2014).  
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1.1.2.2. Cellular redox mechanisms  
Human peroxisomes contain many pro-oxidant and antioxidant enzymes (Del Río and 
López-Huertas, 2016; Stolz et al., 2002). These include enzymes that produce H2O2 
(e.g. FAD oxidases) or degrade it (e.g. catalases) (Del Río et al., 2016), and enzymes 
that produce superoxide (e.g. xanthine oxidase) or degrade it (e.g. xanthine 
dehydrogenase, Cu/Zn superoxide dismutase, and superoxide dismutase 1). 
Peroxisomes also contain enzymes that generate nitric oxide (NO), such as inducible 
nitric oxide synthase (iNOS) (Antonenkov et al., 2010), and enzymes that degrade 
peroxynitrite (ONOO-) such as peroxiredoxins 1 and 5, and enzymes that degrade 
epoxides (e.g. epoxide hydrolase 2), and lipid peroxides (e.g. peroxiredoxin 1, 
peroxiredoxin 5 and glutathione S-transferase kappa) (Fransen et al., 2012; Nordgren 
and Fransen, 2014). Peroxisomes therefore play a key role in the maintenance of the 
cellular redox balance. 
Most of the ROS inside peroxisomes cannot diffuse across the membrane freely 
(Bienert et al., 2006), helping to maintain the normal enzymatic function of cells. 
Peroxisomal lipid synthesis plays a central role in the maintenance of intact cellular 
membranes (Fransen et al., 2012). Many membrane lipid composites are partly 
synthesized or recycled in the peroxisomes, which include VLCFAs, DHA, 
plasmalogens, and cholesterol precursors (Van Veldhoven, 2010). Plasmalogens not 
only regulate the physiological properties of membranes but also trap some free 
radicals (Wallner and Schmitz, 2011). 
It is increasingly clear that changes in peroxisomal metabolism can have a profound 
impact on cellular processes by modulating the composition and concentration of 
specific lipids and redox-derived signaling mediators (Beach et al., 2012; Del Río et al., 
2016). H2O2 and NO are thought to act as signaling molecules in many diseases (A. 
Fisher, 2009). However, it is unclear whether these signals originate from peroxisomes 
and their precise role in terms of intracellular and intercellular signaling are not 
understood. 
 
1.1.3. Peroxisome biogenesis  
At present, 31 proteins are known to be required for the biogenesis and maintenance 
of functional peroxisomes (Islinger et al., 2010). Fourteen different peroxins have been 
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characterized in mammals, including PEX11, which exists as three isoforms (Islinger 
et al., 2010). Peroxisome biogenesis genes can be sorted into three groups (Table 1 
and Figure 1) reflecting the three major tasks of the peroxisome: proliferation, 
membrane assembly and matrix protein import (Fujiki et al., 2014).  
 
Table 1.  Functions of peroxins and other peroxisomal proteins in mammals  
Function  Peroxins 
Matrix protein import PEX1, PEX2, PEX5, PEX6, PEX7,PEX10, 
PEX12, PEX13, PEX14, PEX26 
Membrane assembly PEX3, PEX16, PEX19 
Proliferation PEX11, DDPs, FIS, MFF 
Reproduced from Islinger et al. (2010) 
 
 
Fig.1. A schematic view of peroxisome biogenesis in mammals (Fujiki et al., 2014). PTS: 
peroxisomal targeting sequence. 
 
The import of peroxisomal matrix proteins is mediated by several types of specific 
peroxisomal targeting sequence (PTS) (Waterham et al., 2016). Matrix proteins with 
PTS type 1 or 2 are recognized by the receptors PEX5p or PEX7p in the cytoplasm 
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and are imported by the peroxisomal translocation machinery (Waterham et al., 2016). 
PEX13p and PEX14p together form the peroxisomal docking complex on the 
peroxisomal membrane, which receive the cargo-loaded receptor proteins (Dammai et 
al., 2001; Dodt and Gould, 1996). After docking, the matrix proteins are imported into 
the peroxisomal lumen and the receptor proteins are released from membrane for 
another import cycle, or are directed to the proteasome for degradation (Chang et al., 
1999; Dammai et al., 2001; Waterham et al., 2016).  
PEX3p, PEX16p and PEX19p are responsible for peroxisome membrane biogenesis 
(Waterham et al., 2016). The proliferation of peroxisomes occurs in three stages: 
elongation, constriction, and fission (Schrader and Fahimi, 2006). PEX11 is required 
for elongation and constriction (Koch et al., 2010; Opaliński et al., 2011) and there are 
three isoforms of this protein in humans (PEX11α, PEX11β and PEX11γ) with distinct 
functions (Koch et al., 2012). DLP1/DRP1, FIS1, MFF and GDAP1 are required for 
peroxisome fission (Schrader et al., 2013, 2016).  
 
1.1.4. Metabolic link between peroxisomes and mitochondria  
Mitochondria and peroxisomes share several characteristics: they are small, 
ubiquitous organelles, they demonstrate behavioral plasticity and are highly adaptable 
in terms of structure and abundance according to cellular requirements (Demarquoy 
and Le Borgne, 2015). They are also metabolically linked in at least five ways: (1) 
cooperation in fatty acid β-oxidation to maintain lipid homeostasis; (2) a ROS-related 
sensitive relationship (Fransen et al., 2012); (3) coordinated biogenesis, by sharing 
key proteins of the organelle division machinery (Schrader et al., 2013); (4) potential 
exchange of materials via a vesicular trafficking pathway (Neuspiel et al., 2008), and 
(5) cooperation in anti-viral signaling (Dixit et al., 2010). The β-oxidation products of 
medium chain fatty acids in peroxisomes must be shuttled to mitochondria for further 
oxidation and ATP production (Wanders, 2004). This is the most important metabolic 
connection between these organelles.  
Peroxisomal dysfunction is accompanied by morphological and functional changes in 
the mitochondria, as seen in the peroxisome biogenesis disorder Zellweger syndrome 
and the related knockout mouse models (Baumgart et al., 2001; Dirkx et al., 2005). In 
the cardiomyocytes of PEX5−/− mice, routine electron microscopy revealed an increase 
in the size and number of mitochondrial granules and the presence of 
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megamitochondria (Baumgart et al., 2001). In a diabetes mouse model, catalase 
deficiency increased mitochondrial ROS production in response to fatty acids (Hwang 
et al., 2012).  
Mitochondria and peroxisomes also have a common division mechanism. In mammals, 
components of this mechanism include the dynamin-like protein DLP1/Drp1, which 
forms ring-like oligomeric structures around membrane constructions (Schrader et al., 
2013). The tail-anchored membrane proteins FIS1 and MFF are DLP1 receptors on 
the organelle membranes (Bonekamp et al., 2012; Huybrechts et al., 2009). In the 
abovementioned inter-organelle vesicular trafficking pathway (Neuspiel et al., 2008), 
mitochondria generate small transportation vesicles known as mitochondria-derived 
vesicles (MDVs) containing the mitochondrial anchored protein ligase MAPL, which 
specifically targets peroxisomes (A. Sugiura et al., 2014). However, the physiological 
function of the peroxisome target transportation pathway is not clear. It may play a 
major role in the communication and cooperation of the two organelles or may 
represent the parking control pathway, which senses and responds to abnormalities in 
mitochondrial and peroxisomal functions. 
  
1.1.5. Link between peroxisomes and the endoplasmic reticulum  
The connection between the endoplasmic reticulum (ER) and peroxisomes is both 
physical and functional. During early peroxisome research, peroxisomes were through 
to be formed from the terminal ER (Novikoff and Shin, 1964). However, the discovery 
that peroxisomal enzymes were synthesized on free polyribosomes and directly 
imported from the cytosol supported an autonomous, self-replicating organelle model 
(Lazarow and Fujiki, 1985). Smooth ER segments surround peroxisomes and are often 
laterally affected by each other (Baumgart et al., 1989). PEX3p, a biogenesis peroxin, 
is initially localized in the ER (Hoepfner et al., 2005).  
This metabolic interaction between the peroxisomes and ER is highlighted by the 
phenotype of conditional hepatic Pex5 knockout mice, which feature peroxisome 
ghosts rather than functional peroxisomes (Dirkx et al., 2005). Severe morphological 
alterations were also apparent in the mitochondria of these mice, and significant 
proliferation of the smooth ER was observed. In cases of peroxisome deficiency, ER 
stress pathways are activated, which leads to the deregulation of endogenous sterol 
response pathways (Kovacs et al., 2009, 2012). 
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The most common peroxisome–ER metabolic linkage may involve the biosynthesis of 
ether-phospholipids, which is initiated in the peroxisomes and completed in the ER 
(Braverman and Moser, 2012). For example, the key rate-limiting enzyme in the  
cholesterol biosynthesis pathway is 3-hydroxymethyl glutaryl-CoA reductase (HMG-
CoA reductase), which is localized in peroxisomes (Keller et al., 1986).  
The interaction between the ER and peroxisomes may also regulate calcium 
homeostasis. The smooth ER is known to control free and bound Ca2+ levels in all parts 
of the cell (Krebs et al., 2015). High intracellular concentrations of Ca2+ can lead to 
acute responses, including cell death (Krebs, 1998). Moreover, abnormal Ca2+ levels 
in the long-term can also results in the remodeling of the heart (Schreckenberg et al., 
2015). In rat hepatocytes, the attachment of mature peroxisomes to the ER has been 
observed by three-dimensional (3D) image reconstruction (Grabenbauer et al., 2000), 
suggesting that metabolites are shuttled between these organelles to maintain calcium 
homeostasis. Peroxisomes may also function as calcium reservoirs, thus highlighting 
their role in calcium regulation (Lasorsa et al., 2008). 
 
1.1.6. Peroxisome proliferators and peroxisome proliferator-activated receptors 
1.1.6.1. Peroxisome proliferators 
Various compounds can induce peroxisome proliferation, including certain phthalate 
ester plasticizers, herbicides, leukotriene D4 receptor antagonists, and lipid-lowering 
drugs such as WY-14.643 and ciprofibrate (Lalwani et al., 1983; Reddy and 
Krishnakantha, 1975). In the normal adult rat liver, peroxisomes make up less than 2% 
of the total cytoplasmic volume under physiological conditions (Loud, 1968). After 
treatment with peroxisome proliferators, the peroxisome fraction can rapidly increase 
to 25% (Rao et al., 1988). Peroxisome proliferation is therefore considered protective 
in many diseases because antioxidant enzymes become more abundant (Beier et al., 
1997). However, prolonged exposure to peroxisome proliferators in the liver leads to 
the development of hepatocellular carcinomas in rats and mice (Reddy et al., 1976).  
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Table 2. Classification of peroxisome proliferators. Classification depends on  chemical 
structures or moieties (Misra et al., 2013) 
Fibrate class Clofibrate analogs: methyl clofenapate, nafenopin, fenofibrate, 
gemfibrozil, ciprofibrate  
Acid class Hypolipidic compounds: [4-chloro-6-(2,3-xylidino)-2-
pyrimidinylthio] acetic acid (WY-14.643), 2-chloro-5-(3, 5 
dimethylpiperidinosulfonyl) benzoic acid (tibric acid)  
Phthalate class Phthalate-ester plasticizers: di-(2-ethylhexyl)-phthalate (DEHP), 
di-(2-ethylhexyl) adipate (DEHA)  
 
1.1.6.2. Peroxisome proliferator-activated receptors 
Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear receptor 
superfamily of ligand-activated transcription factors and include three members (𝛼, 𝛽/𝛿 
and 𝛾) encoded by distinct genes located on different chromosomes with a high degree 
of interspecies sequence conservation (Colasante et al., 2015; Desvergne and Wahli, 
1999; Lee and Kim, 2015). Following interaction with PPAR agonists, PPARs are 
translocated to the nucleus and heterodimerize with the retinoid X receptor (RXR) 
which is a promiscuous dimerization partner (Lee et al., 2015). The specific DNA 
targets bound by PPARs are peroxisome proliferator hormone response elements 
(PPREs) (Berger and Moller, 2002). PPARs regulate genes that control cell 
differentiation and metabolic processes such as lipid and glucose homeostasis (Tyagi 
et al., 2011).  
 
1.1.7. Peroxisomal dysfunction and its associated diseases 
The first human diseases linked to peroxisomal dysfunction were discovered by the 
analysis of liver biopsies of Zellweger patients, revealing that the hepatocytes of such 
patients lack functional peroxisomes and to contain abnormal mitochondria 
(Goldfischer et al., 1973). Patients with Zellweger syndrome display a variety of 
symptoms, including impaired brain development, craniofacial abnormalities, 
chondrodysplasia punctata, hypotonia, and liver cirrhosis, and most do not survive 
beyond 1 year of age (Yik et al., 2009). Peroxisomal disorders are classified into two 
groups: disorders of peroxisome biogenesis and single enzyme dysfunction diseases 
(Wanders, 2014). 
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1.1.7.1. Disorders of peroxisome biogenesis  
Pathological mutations in 14 PEX genes lead to disorders of peroxisomal biogenesis, 
with only PEX11α and PEX11γ not associated with any known disorders (Braverman 
et al., 2013). The term Zellweger spectrum disorders (ZSD), which include Zellweger 
syndrome, neonatal adrenoleukodystrophy (NALD) and infantile Refsum disease (IRD), 
has been introduced since these disorders were recognized as a clinical spectrum of 
varying severity (Steinberg et al., 2006).  
The metabolic abnormalities common among these disorders include the accumulation 
of VLCFAs and phytanic acid, elevated bile acid intermediates, and deficient 
plasmalogen biosynthesis (Braverman et al., 2013). Peroxisomes are almost 
completely absent from hepatocytes and fibroblasts, although peroxisomal membrane 
ghosts can be found (Santos et al., 2000). Zellweger syndrome is usually associated 
with death in infancy, but children with NALD may live to school age. Survival to 
adulthood is more likely in IRD (Braverman et al., 2013). Rhizomelic chondrodysplasia 
punctata (RCDP) presents in the neonatal period, with a characteristic skeletal 
dysplasia (Braverman et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 10 
 
Table 3. Pex genes involved in peroxisome diseases. ZS = Zellweger syndrome, NALD = 
neonatal adrenoleukodystrophy, IRD = infantile Refsum disease, RCDP = rhizomelic 
chondrodysplasia punctata (after (Fujiki et al., 2014). 
Gene  Phenotype Peroxisome ghosts 
Pex1 ZS, NALD, IRD + 
Pex2 ZS, IRD + 
Pex3 ZS - 
Pex5 ZS, NALD + 
Pex6 ZS, NALD + 
Pex7 RCDP + 
Pex10 ZS, NALD + 
Pex11β ZS + 
Pex12 ZS, NALD, IRD + 
Pex13 ZS, NALD + 
Pex14 ZS + 
Pex16 ZS - 
Pex19 ZS - 
Pex26 ZS, NALD, IRD + 
 
 
1.1.7.2. Peroxisomal single enzyme deficiencies 
Five different genetic diseases are associated with peroxisomal fatty acid β-oxidation 
deficiency (Wanders, 2014). The most common disorder of peroxisomal β-oxidation is 
X-linked adrenoleukodystrophy (X-ALD), which is caused by mutations in the ABCD1 
gene encoding adrenoleukodystrophy protein (ALDP) (Johannes Berger and Gärtner, 
2006). X-ALD patients are characterized by the accumulation of VLCFAs, especially 
C24:0 and C26:0 in their blood and organs (Ofman et al., 2010). The second most 
common disorder of peroxisomal β-oxidation is D-bifunctional protein (DBP) deficiency, 
which in its severe form mimics Zellweger syndrome in all aspects, including 
craniofacial dysmorphia, neuronal migration defects, and early death (Nascimento et 
al., 2015). Peroxisomal acyl-CoA oxidase deficiency, 2-methylacyl-CoA racemase 
(AMACR) deficiency, and sterol-carrier-protein X (SCPx) deficiency have also been 
reported (Wanders, 2014). Other dysfunctions of peroxisomes are listed in Table 4. 
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Table 4. Peroxisomal single enzyme dysfunction (Wanders, 2014) 
Gene  Disorders Altered function  
Abcd1 X-linked adrenoleukodystrophy Fatty acid β-oxidation 
Acox1 Acyl-CoA oxidase deficiency Fatty acid β-oxidation 
Hsd17b4 
Mfp1 
D-Bifunctional protein deficiency Fatty acid β-oxidation 
Scp Sterol-carrier-protein X deficiency Fatty acid β-oxidation 
Amacr 2-Methylacyl-CoA racemase deficiency Fatty acid β-oxidation 
Gnpat Rhizomelic chondrodysplasia puncatata 
Type 2 
Etherphospholipid biosynthesis 
Agps Rhizomelic chondrodysplasia puncatata 
Type 3 
Etherphospholipid biosynthesis 
Phyh/Pahx Refsum disease Fatty acid α-oxidation 
Agtx Hyperoxaluria type 1 Glyoxylate metabolism 
Baat Bile acid-CoA: amino acid 
N-acyltransferase deficiency 
Bile acid synthesis  
Cat Acatalasemia H2O2 metabolism 
 
 
1.1.7.3. Peroxisomal disease management  
Peroxisomal diseases cannot yet be cured and management is restricted to palliative 
care, including surveillance and developmental assessments (Braverman et al., 2013). 
Oral bile acid supplements ahve improved hepatic function in several ZS patients 
(Maeda et al., 2002; Setchell et al., 1992). However, only anecdotal reports are found 
in the literature (Braverman et al., 2013). Given the benefit of dietary phytanic acid 
restriction in adult Refusm disease, this treatment is often prescribed for surviving 
peroxisome biogenesis disorder (PBD) patients (Braverman et al., 2013). Oral 
supplements of plasmalogen precursors or DHA have not shown evidence of 
therapeutic efficacy (Noguer and Martinez, 2010; Paker et al., 2010). 
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1.2. Peroxisomes and the heart  
1.2.1. The heart and cardiovascular diseases 
The heart is a muscular organ consisting mainly of cardiomyocytes (Mendis et al., 
2015). Studies on the heart date back more than one century, and at that time it was 
already recognized that the heart requires large amounts of calcium, nutrients and 
oxygen (Langendorff, 1895; Winterstein, 1904). Although living standards have 
improved greatly and people are generally more healthy than they were a century ago, 
cardiovascular disease (CVD) remains the most significant cause of death worldwide 
(Mendis et al., 2015). The mechanisms underlying the development of CVDs are still 
poorly understood, leading to unsatisfactory treatments (Mendis et al., 2015). 
 
1.2.2. Metabolic function of the heart  
The energy demands of the heart are enormous, but this organ has limited energy 
reserves. The heart continuously produces adenosine triphosphate (ATP) in its 
mitochondria and can utilize all classes of energy substrates for this purpose, including 
carbohydrates, lipids, amino acids, and ketone bodies (Neely and Morgan, 1974; Opie, 
2004). The main energy resource is the utilization of free fatty acids (D. Fisher et al., 
1980). Glycolysis supports the energy supply to a variable extent. A shift from fatty acid 
β-oxidation to glycolysis has been observed in different disease conditions (Bishop and 
Altschuld, 1970; D. Fisher et al., 1980; Goodwin and Taegtmeyer, 2000). 
 
1.2.2.1. Fatty acid utilization 
The cardiac energy supply may comprise up to 90% fatty acids, or a balanced supply 
may be available in which fatty acids are mixed with other substrates (Grynberg and 
Demaison, 1996). Before fatty acids enter the β-oxidation process, free fatty acids are 
esterified by acyl-coenzyme A (CoA) on the cytoplasmic face of organelle membranes 
(Cheng et al., 2004). Esterified free fatty acids are either transported directly to the 
myocardial triglyceride pool for storage or are converted to long-chain acylcarnitine by 
carnitine palmitoyltransferase (CPT) I in the mitochondria (Lopaschuk et al., 2010; van 
der Vusse et al., 2000).  Esterified fatty acids can also be imported via peroxisomal 
ABCD transporters if mitochondria are overloaded with fatty acids (Baker et al., 2015). 
Some fatty acids, including VLCFAs, cannot be used directly by mitochondria because 
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these organelles do not contain VLCFA-CoA synthetase. For example, C24:0 and 
C26:0 are not substrates of carnitine palmitoyltransferase (CPT) I (Vluggens et al., 
2010) and must be first digested in peroxisomes (Schrader et al., 2013). 
 
1.2.2.2. Glucose utilization 
Cardiomyocytes can utilize intracellular glucose stores or external glucose (Doenst et 
al., 2013). There are several glucose transporters (GLUTs) with diverse expression 
profiles. GLUT1 is the major transporter in the young heart whereas GLUT4 is the 
predominant isoform in the adult heart (Abel, 2004; Aerni-Flessner et al., 2012). 
Following glucose uptake, free glucose is rapidly converted to glucose 6-phosphate 
(G6P) in the smooth ER, and subsequently feeds into many metabolic pathways 
(Doenst et al., 2013).  
 
1.2.2.3. Shift from glycolysis and lactate oxidation (fetal) to fatty acid oxidation 
(adult) in postnatal development 
The fetal heart exists in a relatively hypoxic environment and mainly uses glucose and 
lactate for energy (Scholz and Segar, 2008). Additionally, the workload of the fetal 
heart is relatively low, and the energy derived from glycolysis and lactate oxidation is 
enough to maintain its activity. There is a switch to mitochondrial fatty acid β-oxidation 
after birth in order to accommodate the increased energy demand (Breckenridge, 2014; 
Minners et al., 2000). This switch occurs at both the mRNA and protein levels. For 
example, some genes encoding fatty acid β-oxidation enzymes are significantly 
upregulated in adult rat hearts compared to the neonatal organ (Marín-García and 
Goldenthal, 2002; Minners et al., 2000).  
 
1.2.3. Heart disease markers 
1.2.3.1. Natriuretic peptides 
Atrial natriuretic peptide (ANP), brain (B-type) natriuretic peptide (BNP), and C-type 
natriuretic peptide (CNP) are circulating hormones that regulate blood pressure and 
blood volume (Nishikimi et al., 2006). ANP is synthesized mainly in the atrium, BNP 
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mainly in the ventricle and CNP throughout the central nervous system (Nishikimi et 
al., 2006). 
Natriuretic peptides are wildly used as diagnostic markers. In patients with acute heart 
infarction and chronic heart failure, plasma ANP and BNP levels are markedly 
increased (Morita et al., 1993; Yasue et al., 1994). Higher ANP and BNP levels in 
plasma are believed to compensate for heart failure (Burnett et al., 1986; Mukoyama 
et al., 1991). Furthermore, natriuretic peptides may be involved in the modulation of 
cardiac hypertrophy. Knocking out the Nppa gene encoding ANP in mice leads to 
cardiac hypertrophy, suggesting that ANP also plays a role in the regulation of cardiac 
remodeling (Oliver et al., 1997).  
 
1.2.3.2. Myosin heavy chains  
Myosin heavy chains (MHC) α and β are two cardiac MHC isoforms with distinct 
functions (Krenz and Robbins, 2004). Whereas α-MHC is almost exclusively expressed 
in cardiac tissue, β-MHC is expressed in both cardiac and skeletal muscle (Krenz et 
al., 2004).  
The expression levels of α-MHC and β-MHC are altered in pathological conditions, 
such as cardiac failure or hypertrophy (Krenz et al., 2004), which make these markers 
useful indicators for many cardiac diseases. The predominant isoform in the normal 
mouse heart is α-MHC, but a shift to β-MHC is observed in a mouse heart failure model 
(Harada et al., 1999). The downregulation of α-MHC expression in human hypertrophic 
hearts has also been reported (Miyata et al., 2000; Reiser et al., 2001). The 
upregulation of β-MHC in heart tissue is believed to be detrimental because it inhibits 
cardiomyocyte contractile function (T. Sugiura et al., 1992). 
 
1.2.3.3. Extracellular matrix surrounding cardiomyocytes 
The cardiac extracellular matrix (ECM) is a complex network of matrix proteins in which 
cardiomyocytes, fibroblasts and other cells are embedded (Rienks et al., 2014). The 
ECM not only provides structural support, but also a dynamic and plastic network that 
plays an important role in the regulation of diverse cellular functions. The ECM is 
involved in cell signaling/communication, cell proliferation/differentiation, and cell 
migration (Daley et al., 2008; Lockhart et al., 2011). The cardiac ECM consists 
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predominantly of fibrillar collagen types I and III, as well as collagen types IV, V and VI 
(Fan et al., 2012). Other components of the ECM include laminin, fibronectin, elastin, 
fibrillin, proteoglycans and glycoproteins (Fan et al., 2012).  
 
1.2.4. Potential metabolic causes of heart diseases  
1.2.4.1. Fatty acid metabolic dysfunction affects cardiac structure and function 
Peroxisomal β-oxidation has a critical role in the degradation of long-chain fatty acids 
(LCFAs) and VLCFAs. The accumulation of free fatty acids in cardiomyocytes, which 
often occurs in diabetic or obese individuals, can lead to heart failure (Lopaschuk et 
al., 2010). Fatty acid accumulation can also induce apoptosis in cardiomyocytes 
(Marín-García et al., 2002). The inability to metabolize LCFAs and VLCFAs can lead 
to cardiomyopathy (Marín-García et al., 2002; Strauss et al., 1995). Fatty acids 
accumulating in cardiomyocytes disrupt mitochondrial activity and ATP generation, 
causing the accumulation of ROS (Colasante et al., 2015; Lopaschuk et al., 2010). 
Peroxisomes are actively involved in the protection of the heart by continuously and 
efficiently degrading excess lipid metabolites under pathological conditions.  
 
1.2.4.2. ROS and cardiac diseases  
Lower levels of ROS production can lead to chronic remodeling of the heart, whereas 
high levels of ROS can directly lead to apoptosis in the cardiomyocytes (Sugamura 
and Keaney, 2011). It is therefore interesting that catalase overexpression inhibits 
cardiomyocyte apoptosis by protecting the cells from ROS (Qin et al., 2010). 
Peroxisomal antioxidant enzymes and plasmalogens protect cardiomyocytes via the 
degradation and trapping of ROS and the maintenance of ROS homeostasis. 
 
1.2.5. Peroxisome discovery in the heart 
The main energy source in the adult mammalian heart is fatty acid β-oxidation, and a 
balanced level of ROS is needed for normal heart activity (Colasante et al., 2015; 
Lopaschuk et al., 2010). Peroxisomes are very important in cardiomyocytes because 
they play a central role in fatty acid β-oxidation under fatty acid overload conditions 
and they maintain the ROS balance. It is therefore surprising that few studies have 
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addressed the functions of peroxisomes in the heart and this organ was neglected for 
a long time in terms of peroxisome research. One very important reason for this lack 
of research is that it is difficult to visualize peroxisomes in cardiomyocytes. The first 
systematic descriptions of peroxisomes in the myocardium of rats and mice were 
published 20 years after the discovery of peroxisomes, and were reported at about the 
same time by two different groups (Hand, 1974; Herzog and Fahimi, 1974). 
 
1.2.6. Peroxisomal morphology in the heart 
As is the case for mitochondria, the number of peroxisomes in cardiomyocytes can 
vary (Herzog et al., 1974). Longitudinal sections of cardiomyocytes are optimal for the 
analysis of peroxisome distribution, because these organelles are often found at the 
junction of A and I bands (Herzog et al., 1974). Peroxisomes in cardiomyocytes may 
also be found in the proximity of mitochondria, lipid droplets, the sarcoplasmic 
reticulum, or T-tubules (Colasante et al., 2015). Peroxisomes in the heart share 
characteristics with other peroxisomes, such as an oval shape and a size range of 0.2–
0.5 μm (Colasante et al., 2015; Herzog et al., 1974), but they lack the crystalline 
nucleoids seen in murine liver and kidney cells (Herzog et al., 1974) (Fig. 2). 
Peroxisomal β-oxidation and catalase activity, and peroxisomal proliferation, can be 
stimulated in the rat heart by feeding the animals on a diet containing high levels of 
unsaturated LCFAs (De Craemer et al., 1994; Fahimi et al., 1979; Kvannes et al., 1995).  
 
Fig. 2. Morphology of peroxisomes in cardiomyocytes (from Herzog and Fahimi 1975). 
The peroxisomes in the rat heart are oval in shape (A) and their numbers vary in 
cardiomyocytes (B). The peroxisomes are localized at the junction of A and I bands (B) and in 
the proximity of mitochondria (C). 
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1.2.7. Functions of peroxisomes in the heart  
Peroxisomes may protect the function of the heart (Fahimi et al., 1979). Mice fed on 
an ethanol-rich diet were compared with a control group, revealing an increase in 
catalase activity in the control group, but no significant differences in cardiac function 
parameters. This suggested that higher catalase activity could maintain the normal 
function of the heart against ethanol exposure (Fahimi et al., 1979). This hypothesis 
was supported by experiments in which rats fed on an ethanol-rich diet and also 
administrated a catalase inhibitor (aminotriazole) showed characteristics of cardiac 
damage (Kino et al., 1981). Peroxisomes contain many antioxidants, in addition to 
catalase, such as superoxide dismutase 1, peroxiredoxin I and V, and glutathione 
peroxidase, all of which may be important in cardiomyocytes for scavenging ROS 
(Karnati et al., 2013). Peroxisomes may therefore protect the heart by degrading 
excess fatty acids under pathological conditions (Liepinsh et al., 2013). 
 
1.2.8. Potential role of peroxisomes in heart ischemia  
Acute myocardial ischemia is a pathological condition caused by an insufficient supply 
of blood to the heart, which leads to a sudden reduction in the quantity of nutrients and 
oxygen delivered to heart tissue (Raedschelders et al., 2012). ROS play a key role 
among the many mechanisms of ischemia-reperfusion injury, because  ROS 
generation is detrimental to cardiomyocytes during both the ischemic and reperfusion 
phases (Raedschelders et al., 2012). Efficient reperfusion of the heart tissue during 
the early stage of ischemia is necessary to limit the damaged area and to rescue viable 
cardiomyocytes, but secondary damage may arise due to the sudden burst of ROS 
and the delayed ROS clearance (Raedschelders et al., 2012).  
During an ischemic episode, complete glucose and fatty acid oxidation are inhibited as 
mitochondrial respiration is restricted by the reduced oxygen supply (Kantor et al., 
1999). Glycogenolysis and anaerobic glycolysis briefly continue to produce a small 
amount of ATP until the accumulation of metabolites and end products leads to toxic 
acidosis (Stanley et al., 1997). These factors cause the progressive inhibition and 
disruption of the heart’s normal function. Cardiomyocytes begin to die after 20 minutes 
of ischemia, and the damage becomes irreversible after 6 hours (Jennings and Reimer, 
1991).  
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It has now a consensus that immediate reopening of the obstructed vessels via 
percutaneous coronary intervention (PCI) is among the most effective treatments for 
cardiac ischemia (Saia et al., 2010). After reperfusion, a larger fraction of cellular 
enzymes is released, even more than in the period of hypoxia (Hearse, 1990). Because 
peroxisomes play a central role in the production and scavenging of ROS, they may 
play an important role in cardiac ischemia-reperfusion injury. Studies of peroxisomes 
during ischemia-reperfusion could provide new insights that allow the protection of 
cardiomyocytes from damage. 
 
1.2.9. Regulation by peroxisome proliferator-activated receptors 
PPAR agonists have been used to treat a variety of metabolic disorders, such as 
diabetes and hyperlipidemia (Pol et al., 2015). PPARs are central modulators of 
peroxisomal proliferation and β-oxidation (Cheng et al., 2004; Dreyer et al., 1992). 
However, the functions of PPAR agonists in the heart are unclear. Both beneficial 
functions and adverse effects have been reported, and many PPARs knockout models 
have been studied (Table 5). 
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Target Model Cardiac metabolism alterations Cardiac function alterations Reference 
PPAR𝛼 
  
  
  
  
  
  
  
  
PPAR𝛼−/− Defective lipid and glucose homeostasis  Not indicated  (Djouadi et al., 1998) 
  Decreased fatty acid oxidation, abnormal mitochondria Fibrosis, progressed during aging  
(Watanabe et al., 
2000) 
  
Substrate switch from fatty acid to glucose, inefficient 
ATP generation Normal cardiac function  
(Luptak et al., 2005) 
   Not indicated Systolic ventricular dysfunction, fibrosis  (Loichot et al., 2006) 
   Not indicated Increased oxidative stress, left ventricular dysfunction  (Guellich et al., 2013) 
  
Decreased fatty acid oxidation, increased glucose 
oxidation Normal cardiac function  
(Liu et al., 2011) 
  
Increased fatty acid oxidation, decreased glucose 
oxidation and uptake Ventricular hypertrophy, systolic ventricular dysfunction 
(Finck, 2007) 
𝛼MHC-PPAR𝛼   Not indicated Impaired development  (Peters et al., 2000) 
PPARβ 
  
  
  
  
  
  
PPARβ−/−   Not indicated Embryonic lethality  (Barak et al., 2002) 
  
Decreased fatty acid oxidation and increased glucose 
oxidation, lipid accumulation Cardiac dysfunction, hypertrophy, and reduced survival  
(Cheng et al., 2004) 
𝛼MHC-PPARβ−/− 
Decreased fatty acid oxidation and normal glucose 
oxidation 
Hypertrophy, mitochondrial abnormalities, and cardiac 
dysfunction  
(Liu et al., 2011) 
  
Decreased fatty acid oxidation and glucose oxidation, 
mitochondrial abnormalities Cardiac dysfunction, oxidative damage, and hypertrophy  
(Wang et al., 2010) 
Inducible 𝛼MHC-
PPARβ−/− Normal fatty acid oxidation, increased glucose oxidation Normal cardiac function  
(Burkart et al., 2007) 
𝛼MHC-PPARβ 
Increased fatty acid oxidation and glucose oxidation, 
increased mtDNA Enhanced cardiac contractility  
(Liu et al., 2011) 
Inducible 𝛼MHC-
PPARβ Not indicated Embryonic lethality  
(Barak et al., 1999) 
PPAR𝛾 
 
Inducible 𝛼MHC-
PPAR𝛾−/− 
Decreased fatty acid oxidation, normal glucose 
oxidation Decreased cardiac contractility, modest hypertrophy 
(Luo et al., 2010) 
𝛼MHC-PPAR𝛾1 
Increased triglyceride uptake, increased lipid and 
glycogen stores, and abnormal mitochondria Dilated cardiomyopathy 
(Son et al., 2007) 
Table 5. PPAR knockout and overexpression models and their effects (from Christine et al., 2015) 
) 
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1.2.10. Tools to study heart function and heart disease  
1.2.10.1. Cell lines and models to study peroxisomes in cardiomyocytes 
The mouse atrial cardiomyocyte cell line called HL-1 was derived from AT-1 cells, 
which can be serially passaged and differentiated while maintaining characteristics of 
adult mouse atrial cardiomyocytes (Claycomb et al., 1998) However, the potential to 
study peroxisomes in these cells has not been evaluated. 
 
1.2.10.2. Knockout mouse models of peroxisome deficiency 
Constitutive knockout mouse models have facilitated the investigation of pathogenic 
mechanisms underlying peroxisomal diseases (Baes and Van Veldhoven, 2012a). In 
knockouts of the peroxisomal biogenesis genes Pex2, Pex5 and Pex13, normal 
peroxisomes were replaced with incompetent peroxisomal ghosts (Baes et al., 1997; 
Faust and Hatten, 1997; Maxwell et al., 2003). Pex11 (Pex11α and Pex11β) knockout 
mice have also been generated (Li and Gould, 2002). Interestingly, the Pex11β 
knockout mice had a very similar phenotype to the Pex2, Pex5 and Pex13 knockouts 
and did not survive to adulthood, whereas Pex11α knockout mice had a normal 
lifespan (Li et al., 2002). In the latter model, peroxisomes were present but could not 
proliferate. This model would be suitable to study the role of Pex11α deficiency on 
cardiomyocytes in the adult heart. 
Tissue-specific knockouts have been created by crossing Pex5-loxP and Pex13-loxP 
mice with lines expressing Cre in specific tissues, although not the heart (Baes et al., 
2002; Bjorkman et al., 2002). Tissue-specific knockouts are useful not only to decipher 
the function of peroxisomes in particular cell types and tissues, they are also powerful 
tools to study disease mechanisms when combined with specific disease models 
(Baes et al., 2002).  
Various knockouts of peroxisomal β-oxidation enzymes have been reported (Baes et 
al., 2002). Similar to mice lacking Pex11α, mice lacking the abundant peroxisomal 
membrane protein PMP34 (Van Veldhoven and Mannaerts, 1994) developed normally 
and were fertile, but female mice fed on diets supplemented with phytol showed 
delayed mammary gland development (Baes and Van Veldhoven, 2012b).  
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1.2.10.3. Analysis of heart function in peroxisomal deficiency models 
The Langendorff perfusion system has been widely used to analyze the physiological 
function of the heart in vitro and to establish disease models, such as the ischemia-
reperfusion model. Moreover, an improved cardiomyocyte isolation technique has 
allowed the function of individual murine cardiomyocytes to be analyzed in detail 
(Schlüter and Schreiber, 2005). Because most peroxisomal gene knockout models do 
not survive long after birth, only those with a minor phenotype (e.g. Pex11α) are 
suitable for physiological measurements of cardiac and cardiomyocyte function,  given 
that these techniques require a mature heart and fully differentiated cardiomyocytes 
that contract normally.   
 
1.2.11. Peroxisomes as targets for the treatment of cardiac diseases 
There is now a large body of evidence indicating that metabolic disturbance in the heart 
and a disruption of the ROS balance are the principal factors underlying many heart 
diseases (Doenst et al., 2013). Peroxisomes play a central role in fatty acid β-oxidation, 
ROS production and scavenging, and calcium hemostasis, and also appear to maintain 
the activity of mitochondria as well as protecting cardiomyocytes from ROS injury and 
the accumulation of lipid end products. Investigating the role of peroxisomes in the 
heart may therefore provide novel insights into the pathogenic mechanisms of CVD, 
ultimately providing new treatment routes. Given the complex functional classification 
of peroxisomal proteins, experiments are needed to determine the roles of proteins 
from each of the functional groups. 
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2. Outline and aims of the study 
At the beginning of the research described in this thesis, only limited information was 
available on the morphology and distribution of peroxisomes in the heart. Therefore, 
the first aim of the study was the comparative functional characterization of the 
peroxisomes and the expression of peroxisomal genes in atrial and ventricular 
cardiomyocytes of the normal heart.   
The second aim was to investigate the role of peroxisomes in the heart by the knockout 
or knockdown of two peroxisomal genes with different roles in peroxisome biogenesis. 
The functional ablation of these genes in a mouse model and in a cardiomyocyte cell 
line should provide new insight into the consequences of peroxisomal deficiency in 
cardiomyocytes.  
The first gene selected for analysis was Pex11α, which is known to play an important 
role in peroxisome proliferation. Pex11α knockout mice have been generated and used 
to investigate the function of this gene in the liver (X. Li, Baumgart, et al., 2002). 
Peroxisomes are present in these knockout animals but cannot proliferate under stress 
conditions. The research described in this thesis focused on differences in peroxisomal 
gene expression and morphology between Pex11α knockout mice and wide-type mice, 
and the specific effects of the Pex11α knockout in the heart (changes in molecular 
markers and cardiomyocyte physiological functions), under stress conditions. 
The second gene selected for analysis was Pex14, which is involved in the import of 
cargo into peroxisomes. Three patients with Pex14 mutations have been reported, all 
of whom suffered from severe symptoms and were not able to enjoy a normal life. In 
contrast to Pex11α deficiency, patients with Pex14 deficiency do not possess 
metabolically functional peroxisomes (only membrane ghosts) and all peroxisomal 
metabolic pathways are dysfunctional. The consequences of such a deficiency in the 
heart remain unclear. Therefore, the effect of Pex14 knockdown in HL-1 
cardiomyocytes was investigated, focusing on the impact on cell viability, ECM 
components, and cardiac-specific markers. 
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3. Materials, Methods and Laboratory Animals 
3.1. Materials used in the laboratory 
3.1.1. Chemicals and reagents 
General chemicals used during the research project are listed in Table 6, whereas 
specialized chemicals required for specific experiments are listed separately. 
 
Table 6. General chemicals used during this research project 
Chemical  Company and location 
Acrylamide  Roth, Karlsruhe, Germany  
Agarose LE  Roche, Grenzach-Wyhlen, Germany  
Ammonium molybdate Merck, Darmstadt, Germany 
Ampicillin  Difco, Detroit, MI, USA 
Ascorbic acid  Sigma-Aldrich, Steinheim, Germany  
Bradford reagent  Sigma-Aldrich, Steinheim, Germany  
Bromophenol blue  Riedel-de-Haën, Seelze, Germany 
Citric acid  Merck, Darmstadt, Germany  
Diethylpyrocarbonate (DEPC) Sigma-Aldrich, Steinheim, Germany 
Dimethylsulfoxide (DMSO)  Sigma-Aldrich, Steinheim, Germany 
3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) 
Sigma-Aldrich, Steinheim, Germany 
Dipotassium hydrogen phosphate  Merck, Darmstadt, Germany  
Ethanol  Riedel-de-Haën, Seelze, Germany  
Ethidium bromide  Fluka, Neu-Ulm, Germany  
Ethylene diamine tetraacetic acid (EDTA)  Fluka, Neu-Ulm, Germany  
Formamide  Merck, Darmstadt, Germany 
Glycine  Roth, Karlsruhe, Germany  
Glycerol  Sigma-Aldrich, Steinheim, Germany  
Glycogen  Invitrogen, Karlsruhe, Germany 
Hydrogen peroxide  Merck, Darmstadt, Germany  
β-Mercaptoethanol  AppliChem, Darmstadt, Germany 
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Methanol  Sigma-Aldrich, Steinheim, Germany 
Mowiol 4-88  Polysciences, Eppelheim, Germany 
Paraformaldehyde (PFA)  Sigma-Aldrich, Steinheim, Germany  
Penicillin/streptomycin  PAN Biotech, Aidenbach, Germany  
Ponceau S  Serva, Heidelberg, Germany 
Potassium dihydrogen phosphate  Merck, Darmstadt, Germany  
Potassium hydroxide  Fluka, Neu-Ulm, Germany  
Sodium carbonate  Merck, Darmstadt, Germany  
Sodium chloride  Roth, Karlsruhe, Germany  
Sodium hydrogen carbonate  Merck, Darmstadt, Germany  
Sodium hydroxide  Merck, Darmstadt, Germany  
Sucrose  Merck, Darmstadt, Germany  
Sodium dodecylsulfate (SDS)  Sigma-Aldrich, Steinheim, Germany  
Tetramethylethylenediamine (TEMED)  Roth, Karlsruhe, Germany  
Trishydroxymethylaminomethane (Tris)  Merck, Darmstadt, Germany  
Triton X-100  Sigma-Aldrich, Steinheim, Germany  
Trypan blue  Sigma-Aldrich, Steinheim, Germany  
Tween-20  Fluka, Steinheim, Germany  
Uranyl acetate  Merck, Darmstadt, Germany  
Xylene  Merck, Darmstadt, Germany  
 
3.1.2. Laboratory instruments 
3.1.2.1. General equipment and facilities 
General equipment used during the research project is listed in Table 7, whereas 
specialized equipment required for specific experiments is listed separately. 
 
Table 7. General machines and facilities used in the study 
Instrument name  Manufacturer  
Biocell A10 water system  Milli Q-Millipore, Schwalbach, 
Germany  
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Biofuge Fresco  Heraeus, Hanau, Germany  
Biofuge Pico  Heraeus, Hanau, Germany  
Bio-Rad electrophoresis apparatus  
(Sub Cell GT) system  
Bio-Rad, Munich, Germany  
Dishwashing machine (G 78 83 CD)  Miele, Gütersloh, Germany  
Gel-Doc 2000 gel documentation system  Bio-Rad, Munich, Germany  
Hera cell 240 incubator  Heraeus, Hanau, Germany  
Hera safe, clean bench KS-12  Heraeus, Hanau, Germany  
Ice machine   Manitowoc, Wisconsin, USA  
I Cycler PCR machine  
MiQ2 optical module  
Bio-Rad, Munich, Germany  
Leica DMRD fluorescence microscope  Leica, Wetzlar, Germany  
Leica DC 480 camera  Leica, Wetzlar, Germany  
Leica TP1020 embedding machine  Leica, Wetzlar, Germany  
Leica TCS SP2 confocal laser scanning 
microscope  
Leica, Wetzlar, Germany  
Leica SM 2000R rotation microtome  Leica, Wetzlar, Germany  
Microwave oven MB-392445  LG, Willich, Germany  
Mini-Protean 3 cell gel chamber  Bio-Rad, Munich, Germany  
Microtome stretching water bath  
Type 1003  
Vieth Enno, Wiesmoor, 
Germany  
Multifuge 3 SR centrifuge  Heraeus, Hanau, Germany  
MyiQTM2 two-color real-time PCR cycler and 
detection system  
Bio-Rad, Munich, Germany 
NanoDrop ND 2000  Thermo Fisher Scientific, 
Waltham, MA, USA 
Oven HERAEUS T 5050 EKP  Heraeus, Hanau, Germany  
PH-Meter E163649  IKA, Weilheim, Germany  
Pipettes (0.1-2.5 µL, 0.5–10 µL, 2–20 µL, 10–100 
µL, 20–200 µL, 100–1,000 µL) 
Eppendorf, Hamburg, 
Germany  
Potter-Elvehjem homogenizer 8533024  Braun, Melsungen, Germany  
Power supply - 200, 300 and 3000 Xi  Bio-Rad, Munich, Germany  
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Pressure/Vacuum Autoclave FVA/3  Fedegari, Albuzzano, Italy  
Pump Drive PD 5001  Heidolph Instruments, 
Schwabach, Germany  
SmartspecTM 3000 spectrophotometer  Bio-Rad, Munich, Germany  
Thermo plate HBT 130  Medax, Kiel, Germany  
Thermo mixer HBT 130  HLC, BioTech, Bovenden, 
Germany  
Trans-Blot SD semi dry transfer cell  Bio-Rad, Munich, Germany  
TRIO-thermoblock  Biometra, Göttingen, Germany  
Ultra balance LA120 S  Sartorius-Stedim Biotech, 
Göttingen, Germany  
Ultra Turrax T25 basic homogenizer  Junke & Kunkel, Staufen, 
Germany  
Vortex M10  VWR International, Darmstadt, 
Germany  
Water bath shaker GFL 1083  GFL, Burgwedel, Germany  
 
3.1.2.2. Measurement of cell contraction parameters (Department of Physiology, 
Faculty of Medicine, Justus-Liebig-University) 
Equipment for the measurement of cardiomyocyte contraction is listed in Table 8. 
 
Table 8. System for the measurement of cell contraction parameters 
Instrument Company 
Interface INT4 Scientific Instruments GmbH, 
Heidelberg, Germany 
Microscope TMS-F Nikon, Tokyo, Japan 
Monitor Philips, Eindhoven, Holland 
One-dimensional camera ZK4 Scientific Instruments GmbH, 
Heidelberg, Germany 
Oscillograph Scientific Instruments GmbH 
Heidelberg, Germany 
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3.1.3. Materials and chemicals for cell culture  
3.1.3.1. Materials for HL-1 cell culture and analysis  
The materials used to culture HL-1 cells are summarized in Table 9. 
 
Table 9. Materials for HL-1 cell culture and analysis  
General materials and culture medium  Company Name  
Cover slips (12 mm, 15 mm)  Menzel-Gläser, Braunschweig, 
Germany  
Culture flasks, 25 cm2 Sigma-Aldrich, Steinheim, Germany 
Filter tips and canules  Braun, Melsungen, Germany  
Microtome blades A35  Feather, Köln, Germany  
Molecular weight markers (DNA, RNA)  Fermentas, Baden-Württemberg, 
Germany  
Multi-well cell culture plates (6/12/24-well)  BD Biosciences, Heidelberg, Germany  
Needle (0.55 × 55 mm) BD Biosciences, Heidelberg, Germany 
Syringe (1 ml) BD Biosciences, Heidelberg, Germany 
Syringe  (20 ml) BD Drogheda, Drogheda, Ireland 
Syringe filter (0.2 µm)  Thermo Fisher Scientific, Waltham, MA, 
USA 
Penicillin/streptomycin (5000 U/ml) Thermo Fisher Scientific, Waltham, MA, 
USA  
Nunc-Immuno MicroWell 96-well solid 
plates 
Thermo Fisher Scientific, Waltham, MA, 
USA 
 
3.1.3.2. Chemicals for HL-1 cell culture  
The HL-1 cells require specific media components to grow and maintain their 
cardiomyocyte characteristics, which are listed in Table 10. 
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Table 10. Media components required for the cultivation of HL-1 cells 
Chemical Vendor Catalog # 
Claycomb medium Sigma-Aldrich, 
Steinheim, Germany 
51800C 
Fetal bovine serum Sigma-Aldrich, 
Steinheim, Germany 
F2442 
Penicillin/streptomycin (104 U/ml 
and 104 g/ml, respectively) 
Sigma-Aldrich, 
Steinheim, Germany 
P4333 
(±)-Norepinephrine (+)-bitartrate 
salt 
Sigma-Aldrich, 
Steinheim, Germany 
A0937 
L-Ascorbic acid, sodium salt Sigma-Aldrich, 
Steinheim, Germany 
A7506 
L-Glutamine, 200 mM Sigma-Aldrich, 
Steinheim, Germany 
G7513 
Trypsin-EDTA (0.05% trypsin in 
0.02% EDTA-Na) 
Sigma-Aldrich, 
Steinheim, Germany 
T3924 
Trypsin inhibitor type I-S, saoybean Sigma-Aldrich, 
Steinheim, Germany 
T6522 
Dulbecco’s PBS (Ca2+ and Mg2+ 
free) 
Sigma-Aldrich, 
Steinheim, Germany 
D8537 
Fibronectin (1 mg/ml) Sigma-Aldrich, 
Steinheim, Germany 
F-1141 
Gelatin from bovine skin Sigma-Aldrich, 
Steinheim, Germany 
G9391 
Distilled water, cell culture grade Sigma-Aldrich, 
Steinheim, Germany 
W3500 
Cryovials, 2 ml round bottom Corning, Corning, NY, 
USA 
430289 
Sterile acrodisc syringe filters, 0.2 
µm 
Gelman Sciences, 
Colorado, USA 
4192 
Mr. Frosty 18-tube freezing 
container 
Nalgene Nunc, 
Rochester, NY, USA 
7-5100-0001 
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3.1.3.3. Solutions for the preparation of mouse primary cardiomyocytes  
The solutions used for the preparation of cardiomyocytes are listed in Table 11. 
 
Table 11. Solutions for the preparation of mouse primary cardiomyocytes 
Name  Composition 
Calcium stock solution CaCl2 100 mM 
Powell medium  
 
NaCl 110 mM 
NaHCO3 25 mM 
Glucose 11 mM 
KCl 2.6 mM 
KH2PO4 1.2 mM 
Mg2SO4 1.2 mM 
Collagenase buffer Powell Medium 40 ml 
Collagenase 20 mg 
Calcium stock solution 12.5 μl 
 
3.1.4. Proteins and enzymes 
Proteins (including enzymes) are listed alphabetically with the corresponding suppliers 
in Table 12. 
 
Table 12. Proteins and enzymes used in the study 
Proteins (including enzymes)  Company name and location 
Bovine serum albumin (BSA)  Roth, Karlsruhe, Germany 
DNase I  Sigma-Aldrich, Steinheim, Germany 
Immunostar-alkaline phosphatase  Bio-Rad, Munich, Germany 
Milk powder  Roth, Karlsruhe, Germany 
Precision plus protein standards, dual 
color and unstained  
Bio-Rad, Munich, Germany 
Primary antibodies  Various companies, see Table 14 
Secondary antibodies  Various companies, see Table 14 
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SuperScript II reverse transcriptase  Invitrogen, Karlsruhe, Germany 
Taq DNA polymerase  Eppendorf, Hamburg, Germany 
Protease-inhibitor Mix M (39102) SERVA Electrophoresis GmbH, 
Heidelberg, Germany 
 
3.1.5. Kits 
All the kits used in this study are listed in Table 13. 
 
Table 13. List of kits with corresponding suppliers 
Kits Company name Kits Company name 
Fibrous tissues RNA isolation Kit Qiagen, Hilden, Germany 
RNeasy kit  Qiagen, Hilden, Germany 
RT-PCR kit  Invitrogen, Karlsruhe, Germany 
Maxima SYBR Green/ROX qPCR 
Master Mix 
Thermo Fisher Scientific, Waltham, MA, 
USA 
Lipofectamine 3000 Transfection Kit Invitrogen, Karlsruhe, Germany 
Amplite Fluorimetric H2O2 Assay Kit AAT Bioquest, Sunnyvale, CA, USA 
Plasmid Midi Kit (Cat No./ID  12143) Qiagen, Hilden, Germany 
 
3.1.6. Primary and secondary antibodies 
The primary and secondary antibodies used in this study are listed in Table 14.  
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Table14. Primary and secondary antibodies used in this study. Ms = mouse; Rb = rabbit; WB = western blot analysis; IF = immunofluorescence 
analysis. 
Target Host Source; catalog number Lot or Catalog 
number 
Dilution 
WB 
Dilution 
IF 
Catalase (CAT) 
 
Rb Gift from Denis I Crane, School of Biomolecular 
and Biophysical Science, Griffith University, 
Nathan, Brisbane, Australia 
In house  1:10,000 1:2,000 
GAPDH  Ms HyTest Ltd, Intelligate, Turku, Finland; 5G4 09/10-G4-C5 1:20,000 - 
Peroxisomal biogenesis factor 
13 (Pex13p) 
Rb Gift from Denis I Crane (address see above) In house 1:6,000 1:2,000 
Peroxisomal biogenesis factor 
14 (Pex14p) 
Rb Gift from Denis I Crane (address see above) In house 1:20,000 1:4,000 
PMP(peroxisomal membrane 
protein) 70 
Rb Gift from Alfred Völkl, Department of Anatomy 
and Cell Biology II, University of Heidelberg, 
Heidelberg, Germany 
In house 1:250 - 
Superoxide dismutase 2 
(SOD2) 
Rb Research Diagnostics, Inc., Flanders, NJ, USA RDI-
RTSODMabR 
1:6,000 1:5,000 
Anti-mouse IgG alkaline 
phosphatase  
Goat Sigma-Aldrich, Steinheim, Germany  A3562 1:20,000 - 
Anti-rabbit IgG alkaline 
phosphatase 
Goat Sigma-Aldrich, Steinheim, Germany A3687 1:20,000 - 
Anti-rabbit-IgG Alexa Fluor 488 Donke
y 
Molecular Probes/Invitrogen, Karlsruhe, 
Germany 
A21206 - 1:600 
Anti-mouse-IgG Alexa Fluor 555 Horse Molecular Probes/Invitrogen, Karlsruhe, 
Germany  
A21422 - 1:600 
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3.2. Software used for recording and analyzing data 
The software used in this study is listed in Table 15. 
 
Table 15. Software used for data recording and analysis 
Function Software 
Text processing Microsoft Word, Office 2010, Microsoft 
Image process Photoshop CS5, Adobe 
Data analysis and Graph making GraphPad Prism 6, Graphpad Software 
Microsoft Excel, Office 2010, Microsoft 
Absorbance measurement, H2O2 assay Mikro Win 2000, Mikrotek Laborsysteme 
GmbH 
RNA concentration determination  Nanodrop 2000 software, Thermo Fisher 
Scientific  
Quantitative PCR  iQ5 Optical System Software, Bio-Rad 
Semi-quantitative PCR documentation Gel Doc 2000 software, Bio-Rad 
Cell shorting measurement MUCEL, Scientific Instruments GmbH  
 
 
3.3. Bioinformatics tools 
3.3.1. GenBank 
GenBank (http://www.ncbi.nlm.nih.gov) is a database that contains nucleotide 
sequences (Benson et al., 2016). PubMed is the integrated biomedical journal 
literature portal, which was used for literature searches in this study 
(https://www.ncbi.nlm.nih.gov/pubmed). The basic local alignment search tool (BLAST) 
allows sequence similarity searches against GenBank and other sequence databases 
(Benson et al., 2016). In this study, the specificity of primer binding sites was checked 
using BLAST.  
 
3.3.2. Databases of expressed sequence tags  
The database of expressed sequence tags (dbEST) is a collection of short cDNA clone 
fragments from diverse cDNA libraries (Boguski et al., 1993). These fragments can be 
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used to identify specific genes or gene transcripts (Adams et al., 1991). Expressed 
sequence tags (ESTs) are the primary source of data for gene expression and 
annotation studies, including species-restricted, organ/tissue-specific and cell type-
specific expression profiles (Benson et al., 2016). EST sequence data in dbEST is 
annotated with the species and tissue of origin and the type of library. 
 
3.3.3. UniGene 
UniGene (http://www.bioinfo.org.cn/relative/NCBI-UniGene.htm) is a database of 
transcript sequences that partitions GenBank entries into gene-oriented clusters 
representing a unique gene. Each entry is linked to information such as the source 
species and tissue, and the genomic map location of the corresponding gene. 
 
3.4. Mice  
3.4.1. Wild-type mice 
Wild-type C57BL/6J mice were obtained from the Central Animal Facility (Zentrales 
Tierlabor) of the Justus-Liebig-University Giessen, Germany. Breeding and handling 
was approved by the Regierungspraesidium (Governmental Commission of Animal 
Care), permit number V 54-19 C 20/15 c GI 20/23. Eight wild-type mice (19–24 weeks 
old) were used to analyze peroxisome distribution in different parts of the heart. Three 
newborn pups, four wild-type pups at postnatal day 2 (P2), and four mice aged 8 weeks 
were used to investigate the developmental changes of peroxisomes in mouse hearts.  
 
3.4.2. Pex11α knockout mice 
The Pex11α knockout mice were generated and described previously (X. Li, Baumgart, 
et al., 2002). Briefly, exon 2 and exon 3 of the Pex11α gene were replaced with a PGK-
neo cassette by homologous recombination in embryonic stem cells. Pex11α knockout, 
heterozygotes and wild-type mice were identified by testing tail DNA. Breeding and 
handling was approved as above. Nine Pex11α+/+, three Pex11α+/- and nine Pex11α-/- 
mice (9–27 weeks old) were used in this study. Six wild-type mice and six Pex11α 
knockout mice (12–50 weeks old) were used to measure cell shorting. Six wild-type 
mice and five Pex11α knockout mice were used for ischemia-reperfusion experiments. 
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Animals were housed under standard conditions (12 h light and 12 h dark) in the 
Central Animal Facility of the Justus-Liebig University Giessen. All animal experiments 
were approved by the German Government Commission of Animal Care. 
 
3.5. Methods 
3.5.1. Data mining  
For each peroxisomal gene of interest, data mining involved checking the dbEST 
profile for the heart and liver to find the transcripts per million (TPM) value. The liver 
was used as a reference given that this organ contains the largest number of 
peroxisomes in mammals (Islinger et al., 2010). The TPM values of peroxisome-related 
genes in the heart and liver libraries were acquired from the UniGene database, via 
the NCBI portal. 
 
3.5.2. HL-1 cells 
HL-1 atrial cardiomyocytes were obtained from Dr. William Claycomb (Louisiana State 
University Medical Center). Cells from passages 51–60 were used in this study. HL-1 
cells are derived from the mouse atrial tumor lineage AT-1 and retain many 
characteristics of differentiated atrial cardiomyocytes (Claycomb et al., 1998). However, 
the cells used in this study did not display a beating phenotype. 
 
3.5.2.1. HL-1 cell culture 
HL-1 cells were grown in Claycomb medium supplemented with batch-specific 10% 
fetal bovine serum (FBS), 100 U/ml penicillin + 100 µg/ml streptomycin, 0.1 mM 
norepinephrine, and 2 mM L-glutamine. One day before seeding, the flasks were 
incubated overnight with 0.02% Bacto gelatin in 0.5% fibronectin. The cells were 
passaged twice per week, each time by seeding ~3 × 106 cells into a new 25 cm2 flask, 
as previously described (Claycomb et al., 1998).  
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3.5.2.2. Transfection of HL-1 cardiomyocytes with Pex14 siRNA 
Cell culture plates (6/12/24 wells) with or without cover slips were coated with 0.02% 
Bacto gelatin in 0.5% fibronectin overnight. For six-well plates, 1.5–2×105 cells were 
seeded in each well. For 12/24-well plates, the cell number was reduced proportionally 
according to the surface area of the well. Once the cells had attached, transient 
transfection experiments were carried out using Lipofectamine 3000 reagent 
(Invitrogen) in Opti-MEM I Reduced Serum Medium (Thermo Fisher Scientific). For 
each well, a mixture of Lipofectamine/siRNA complex solution was prepared by mixing 
10 µl of Lipofectamine 3000 reagent and 150 pmol Pex14 siRNA in the Opti-MEM I 
medium, and a final volume of 250 µl was added to each well. The homogeneous 
dispersal of the complex was achieved by gentle shaking. Cells transfected with 
AllStars Negative Control siRNA (Qiagen) under the same conditions were used as the 
control group. After 48 h, 96 h and 6 days, the cells were collected for further analysis. 
 
3.5.3. Cardiomyocyte cell shorting measurements 
3.5.3.1. Isolation of adult mouse ventricular cardiomyocytes 
Myocytes were prepared and their contraction was measured in the laboratory of 
Professor Schlüter, Department of Physiology, Faculty of Medicine, Justus-Liebig-
University. Ventricular heart muscle cells were isolated from mice as previously 
described (Schlüter and Piper, 2005; Schlüter and Schreiber, 2005) with a slightly 
modified protocol. Briefly, operation scissors (Aesculap, Tuttlingen) and forceps 
(Eickemeyer, Tuttlingen) were disinfected before use. Mouse hearts were excised 
together with the lungs after cervical dislocation and transferred rapidly to physiological 
NaCl (0.9% w/v) (Braun Melsungen AG, Melsungen), followed by mounting on the 
cannula of a circulating constant-flow perfusion system (designed by the working group 
of Prof. Schlüter). The hearts were perfused with 5 ml calcium-free Powell medium 
(Section 3.1.3.3) in a non-re-circulating manner, then for 25 min in a re-circulating 
manner in Powell medium supplemented with type II collagenase (Type CLSII, 
Biochrom, Berlin) and calcium. Thereafter, the ventricular tissue was cut out, minced 
using a tissue chopper (HSE, March-Hugstetten), and incubated for another 5 min in 
re-circulating buffer at 37°C. After incubation, the cell solution was filtered through a 
200-µm polyamide mesh (NeoLab, Heidelberg). The filtered material was centrifuged 
at 25 g (300 rpm) using a Megafuge 2.0 (Kendro, Hanau) and resuspended in buffer 
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with a gradually increasing calcium concentration to a final value of 1 mM, before 
transfer to the culture medium (Schlüter and Piper, 2005). 
 
3.5.3.2. Cell shorting measurements 
Isolated cells were separated in culture dishes (Falcon 3001/3004; Becton Dickinson, 
Heidelberg) and allowed to settle and adhere lightly for 1 h. Cell shortening was 
measured as previously described (Langer et al., 2003). Briefly, cardiomyocytes from 
the hearts of wild-type and Pex11α knockout mice were analyzed using a cell-edge 
detection system. Two AgCl electrodes sending out electrical stimuli were immersed 
in the culture medium. Four sets of cell shortening, contraction and relaxation velocity 
data (Table 16) were recorded, and the average was calculated (Hill et al., 2013). 
 
Table 16. Cardiomyocyte parameters recorded and calculated in this study. 
Parameters Definition 
Diastolic cell length The maximum cell length when contracting 
Systolic cell length The minimum cell length when contracting 
Time to peak The time from the beginning of contraction  to the 
maximum contraction 
Conmax in μm/s The maximum contraction velocity 
Relmax in μm/s The maximum relaxation velocity 
dL/L% 
 
The dL is the change from diastolic to systolic cell length, 
and dL/L% is cell shortening as a percentage of diastolic 
cell length 
 
3.5.4. Ischemia-reperfusion model in male Wister rat hearts 
The following experiments were carried out in collaboration with Professor Böning 
(Department of Cardiovascular Surgery, University Hospital Giessen and Marburg, 
Campus Giessen, Giessen, Germany), who kindly provided us the rat samples 
((Böning et al., 2014). 
Wistar rats (Janvier Laboratories, France), 4–5 months of age and 464–597 g in weight 
were anesthetized with isoflurane (2.5% isoflurane and 97.5% oxygen) and killed by 
cervical dislocation. The hearts were rapidly excised, and the aorta was cannulated for 
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retrograde perfusion and connected to a Langendorff perfusion system as described 
by Böning et al. (Böning et al., 2014). The rat heart ischemia-reperfusion model used 
in this study was performed in two steps: (1) 90 min ischemia by aortic clamping and 
(2) reperfusion for 90 min. The heart was exposed to intervention for less than 4 h in 
total. Afterwards the hearts were stored at -80ºC and later processed for mRNA and 
protein isolation. 
 
3.5.5. Catalase activity assay on mouse heart homogenates and cell lysates 
Catalase protects cells from the accumulation of H2O2 by converting it into water and 
oxygen (Michiels et al., 1994). H2O2 is a major ROS and is a product of aerobic 
metabolism in the heart (Boveris and Chance, 1973). Catalase activity was measured 
based on the formation of a yellow complex due to the reaction between molybdate 
and H2O2.  The solutions needed for the catalase assay are listed in Table 17 and the 
components of the three blank solutions are listed in Table 18. The color change 
after the catalase reaction is shown in Figure 3. 
Table 17. The solutions needed for the catalase assay 
Function Component 
Substrate 65 µM H2O2 in phosphate-buffered saline (PBS) 
Stop solution and color 
indicator 
32.4 mM ammonium molybdate in PBS 
Sample solution For tissue: the tissue and lysis buffer ratio is 1:50 (w/w) 
For cells: 300 µL of cell lysis solution was added to each 
well of a six-well plate 
 
Table 18. The composite of the blank solutions 
Blanks Component 
Blank 1 1.0 ml substrate, 1 ml molybdate, 50 µl sample solution 
Blank 2 1.0 ml substrate, 1 ml molybdate, 50 µl lysis buffer 
Blank 3 1.0 ml PBS, 1.0 ml molybdate, 50 µl lysis buffer 
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Fig.3. Measurements of catalase activity in heart tissue homogenates. From left to right 
the samples are blank 3, blank 2, blank 1, heart and liver. Blank 3 is the sample without the 
H2O2 substrate, revealing the colorless molybdate solution. In Blanks 2 and 1, the H2O2 reacted 
with molybdate to form a yellow complex. The heart homogenate reacted with the H2O2, but 
the surplus reacted with molybdate to form a weaker yellow color. The liver homogenate 
reacted with all of the H2O2 leaving no surplus, and was used as a positive control in these 
experiments. 
 
The catalase assay was carried out as previously described (Goth, 1991) with some 
modifications. Briefly, tissue pieces and cells were homogenized in cell lysis buffer (25 
mM Tris-HCl, 1 mM EDTA, 1 mM DTT, 250 mM sucrose, pH 7.8) at the ratio shown in 
Table 17. We prepared 40 ml of reaction substrate containing 65 µM H2O2 and 40 ml 
of stop solution containing 32.4 mM ammonium molybdate. We then mixed 50 µl of 
homogenate with 1.0 ml of the substrate and incubated for 3 min at 37°C. The 
enzymatic reaction was stopped by adding 1.0 ml of ammonium molybdate solution, 
and the absorbance at 405 nm was measured. The H2O2 solution was always freshly 
made before each measurement. The catalase activity was calculated using the 
following formula: 
Catalase activity (kU/L) = (ASample – ABlank-1) / (ABlank-2 – ABlank-3) × 271 
 
3.5.6. Fluorimetric hydrogen peroxide assay 
H2O2 levels were measured using the Amplite Fluorimetric Hydrogen Peroxide Assay 
Kit (AAT Bioquest). Briefly, cells cultured in six-well plates were washed with PBS at 
different time points after treatment and then collected in cell lysis solution. In each 
well, 50 μl of the H2O2 reaction mixture  was added (red peroxidase substrate and 
horseradish peroxidase from the kit). Then the H2O2 standard solution, blank control 
samples, and test samples were added, making a final assay volume of 100 μl per well. 
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The plates were incubated at room temperature for 15 min, protected from the light. 
The increase in fluorescence was monitored with a fluorescence plate reader at 
λExcitation/λEmission = (540 ± 10)/(590 ± 10) nm. 
 
3.5.7. Methylthiazole tetrazolium (MTT) assay 
The MTT colorimetric assay (Sigma-Aldrich) is used to determine the viable cell 
number in proliferation and cytotoxicity studies. This assay is based on the cleavage 
of the yellow tetrazolium salt MTT by mitochondrial dehydrogenases to form a soluble 
blue formazan product. The amount of formazan produced is directly proportional to 
the number of living cells (Sylvester, 2011). In this study, the effect of treatments on 
the viability of HL-1 cardiomyocytes was evaluated using the MTT assay as previously 
described (Vijayan et al., 2011) with slight modifications. Briefly, after treatment with 
0.5% ethanol and Pex14 siRNA for 48 h, cells were washed and incubated with 0.5 
mg/ml MTT in cell culture medium for 3 h. The formazan crystals in viable metabolic 
cells were dissolved in isopropanol and the absorbance was measured at 570 nm. The 
percentage of viable cells was calculated using the following formula:  
%viable cells = A570 of treated cell / A570 of non-treated cells × 100 
 
3.5.8. Trypan blue exclusion test  
The viability and number of HL-1 cardiomyocytes was assessed using the trypan blue 
exclusion test, which is based on the principle that viable cells have intact membranes 
that prevent the uptake of the dye, whereas dead cells have broken membranes which 
allow staining (Strober, 2015). The cell suspension (0.5 ml) was incubated with 0.1 ml 
trypan blue solution (0.5% w/v in PBS) for 5 min at room temperature. Afterwards, 
viable cells with clear cytoplasm and dead cells with blue cytoplasm were counted 
using a Neubauer Cell Counting Chamber (Brand GMBH, Wertheim, Germany) by 
counting four fields with 16 squares each. The numbers of living and dead cells were 
used to calculate the cell viability, as well as the total number of cells using the formula 
shown below. 
% viable cells = [1.00 – (Number of blue cells ÷ Number of total cells)] × 100 
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3.6. Molecular biological and morphological experiments on mouse tissue 
and cells 
3.6.1. Molecular biological experiments for gene expression analysis 
The reverse transcription polymerase chain reaction (RT-PCR) is a highly sensitive 
and specific method to detect and quantify rare transcripts (Marone et al., 2001). The 
RT-PCR procedure includes RNA extraction, reverse transcription, PCR amplification 
and quantitative analysis (Marone et al., 2001). 
 
3.6.1.1. RNA isolation from heart tissue and HL-1 cells and reverse transcription 
to generate cDNA  
Total RNA was isolated from (1) HL-1 cells (passage 51–60), (2) newborn and adult 
whole hearts, and (3) the left atrium, right atrium, left ventricle and right ventricle, using 
RNAzol RT (Sigma-Aldrich) and the isolation protocol of the manufacturer. The heart 
samples were taken from wild-type (Pex11α+/+), Pex11α+/- and Pex11α-/- mice. 
 
3.6.1.1.1. Isolation of total RNA from mouse heart tissue 
Mice were killed by cervical dislocation and the hearts were rapidly excised and stored 
in liquid nitrogen. For mRNA isolation, frozen tissue samples were transferred to 
RNAzol RT solution supplemented with 10% v/v glycerol (1 ml per up to 100 mg of 
tissue), and quickly homogenized in an Ultra Turrax T25 basic homogenizer for 30 s 
on ice. All further steps were carried out according to the RNAzol RT protocol. 
 
3.6.1.1.2. Isolation of total RNA from HL-1 cells 
HL-1 cells were harvested directly from the cell culture dish. After removing the medium, 
RNAzol RT solution supplemented with 10% v/v glycerol was added directly to each 
well (at least 1 ml of RNAzol RT per 10 cm2 according to the RNAzol RT protocol), 
before scraping the cells into collection tubes. The cells were lysed by pipetting, and 
subsequent steps were carried out according to the RNAzol RT protocol. 
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3.6.1.1.3. Quality control and cDNA synthesis 
The isolated total RNA was dissolved in RNase-free water and stored at –80°C. The 
quantity was determined by measuring the absorbance ratio at 260 and 280 nm using 
a Bio‐Rad spectrophotometer. DNase I was added to to remove trace of genomic DNA 
by mixing 1 μg of RNA sample with 10× DNase I reaction buffer, 1 U/μl DNase I (Amp 
Grade) and DEPC-treated water to 10 µl, then incubating for 15 min at room 
temperature. The DNase I was then inactivated by adding 1 μl 25 mM EDTA and 
heating at 65°C for 10 min. The purified total RNA (1-2 µg) was then reverse 
transcribed to produce first-strand cDNA using Superscript II reverse transcriptase 
(Invitrogen) according to the manufacturer’s protocol. 
 
3.6.1.2. RNA analysis by semi-quantitative RT-PCR 
Semi-quantitative PCR was carried out in a total reaction volume of 25 µl containing 
0.1 µg cDNA and the primers listed in Table 19. The reaction mixture was heated to 
95°C for 10 min, followed by 30–35 cycles of denaturation at 95°C for 30 s, annealing 
at the appropriate primer-specific annealing temperature (Table 19) for 30 s, and 
extension at 72°C for 60 s. The products were separated by agarose gel 
electrophoresis and bands were quantified using the Bio-Rad Gel Doc 2000 system.  
All primers used for this study were laboratory stocks in the working group of Prof. 
Baumgart-Vogt. 
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Table 19. The RT-PCR primers used in this study.  
Genes NCBI reference 
of genes 
Forward primers (5′→3′) Reverse primers (5′→3′) Tm 
(°C) 
Product 
(bp) 
Pex5 NM_001277805.1 GAGTGAAGAAGCAGTGGCTGCATAC GGACAGAGACAGCTCATCCCTACAA 62 508 
Pex6 NM_145488.1 AGTGTAAAGGGACCGGAGCTCATC TCTAGCCCTTCCTCTAGGTCTCGAA 60 515 
Pex7 NM_001161825.1 GTGAAGACCACAGGAGTACGGATTG CCGTGAGACAAACAGGGTCATAGA 62 409 
Pex13   NM_023651.4 GACCACGTAGTTGCAAGAGCAGAGT CTGAGGCAGCTTGTGTGTTCTACTG 65 565 
Pex14 NM_019781.2 CCAGACAGTGACTCAGGTGCAGA TGGTGCCAGGTGGTCAAGATACT 62 982 
Gnpat NM_010322.3 TGAGGACGTGCAAGCCTTTG TCCAGAAGCTGACGGGTGAA 62 759 
Acox1 NM_015729.3 CTGAACAAGACAGAGGTCCACGAA TGTAAGGGCCACACACTCACATCT 63 565 
Aldp NM_007435.2 GAGGGAGGTTGGGAGGCAGT GGTGGGAGCTGGGGATAAGG 65 465 
Acox3 NM_030721.2 GCCAAAGCTGATGGTGAGCTCTAT AGGGGTGGCATCTATGTCTTTCAG 62 813 
Pmp2 NM_008993.2 TCCTAAAGCTCTACCCGGTGCTC AGGTGTCCACATCCTCCAGTTCA 63 395 
Pmp24 NM_021534.3 ACCCCTCCAAGTAACACAGTCCAA CATACAAGCTTGACACGTGCTGTG 62 577 
Pmp34 NM_011399.3 GGGTCAAAGGTCAGCGTTCTTCT ACTTCCCAGGGTCCTGTTTTCTG 62 461 
Pmp35 NM_001163305.2 GATGGGGAGGATCAGGTGAAAAC CCAAGGAGGCGTTCTGTCAAAGT 62 611 
Abcd3 NM_008991.2 CTGGGCGTGAAATGACTAGATTGG AGCTGCACATTGTCCAAGTACTCC 62 523 
Abcd4 NM_001286759.1 GCTGCACAGAATGGAGTTGA CAAAGCTCTTCAGGGTGGAG 62 296 
Pparα NM_011144.6 AGACCGTCACGGAGCTCACA GGCCTGCCATCTCAGGAAAG 68 584 
Pparβ NM_011145.3 CACCGAGTTCGCCAAGAACA AGAGCCCGCAGAATGGTGTC 60 363 
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Pparγ NM_001127330.1 TCCGTAGAAGCCGTGCAAGA CACCTTGGCGAACAGCTGAG 62 441 
Gapdh NM_008084 CACCATGGAGAAGGCCGGGG GACGGACACATTGGGGGTAG 62 418 
28S 
rRNA 
NR_003278.1 CCTTCGATGTCGGCTCTTCCTAT GGCGTTCAGTCATAATCCCACAG 62 254 
β-actin NM_007393.5 GTGGGCCGCTCTAGGCACCAA CTCTTTGATGTCACGCACGATTTC 65 540 
 
 44 
 
3.6.1.3. RNA analysis by real-time quantitative PCR 
Real-time quantitative PCR (qRT-PCR) involves the addition of a fluorescent label to 
the PCR product allowing the quantity to be measured in real time. We used SYBR 
green, which can bind to double-stranded DNA or label sequence-specific DNA 
primers or cDNA probes (Ponchel et al., 2003). The computer transformed the signal 
detected by the sensor to the threshold cycle (Ct) value, which is proportional to the 
initial amount of cDNA (Ponchel et al., 2003). The primers were synthesized by 
Eurofins MWG Operon. A 20-μl qRT-PCR reaction mixture was prepared as follows  
(Table 20).  
 
Table 20. The qRT-PCR components. 
Component Volume  
cDNA template 1 μl 
Maxima SYBR Green/ Fluorescein qPCR 
Master Mix (2 ×) 
10 µl 
Forward primer 0.3 μM 
Reverse primer 0.3 μM 
Water, nuclease-free To 20 µl 
 
Each qRT-PCR was performed in duplicate using an iCycler iQ System according to 
the manufacturer’s protocol (Bio-Rad). Heating to 95°C for 8 min was followed by 45 
cycles of denaturation at 95°C for 20 s, annealing at the appropriate primer-specific 
temperature (Table 21) for 30 s, and extension at 72°C for 30 s. Before each 
experiment, melt curves and primer efficiencies were determined for each primer pair 
to confirm the specificity of the PCR product using cDNA from the control group. The 
qRT-PCR data were normalized against the Gapdh and 28S rRNA housekeeping 
genes and were presented as relative expression levels using the ΔΔCt method (Yuan 
et al., 2006). 
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Table 21. The qRT-PCR primers used in this study. 
Gene  NCBI reference Forward primers (5′→3′) Reverse primers (5′→3′) Product (bp) 
Cat NM_009804.2 GGAGGCGGGAACCCAATAG GTGTGCCATCTCGTCAGTGAA 102 
Abcd1  NM_007435.1 ACAGTGCCATCCGCTACCTA ATGAGCTACTAGACGGCTTCG 65 
Acox1  NM_015729.3 CCGCCACCTTCAATCCAGAG CAAGTTCTCGATTTCTCGACGG 86 
Acox2  NM_001161667.1 ACGGTCCTGAACGCATTTATG TTGGCCCCATTTAGCAATCTG 125 
Acox3  NM_030721.2 CTGTTTTGCTCTCACCGAACT TCGAAATCCGGGGAATGTAAGAT 89 
Pex5 NM_001277805.1 AATGCAACTCTTGTATCCCGAG GGCGAAAGTTTGACTGTTCAATC 91 
Pex7  NM_001161825.1 GACAGGTGCGGTTGACTGTA GCGTGGAACGGTGAAAAT 150 
Pex11α NM_011068.1 ACTGGCCGTAAATGGTTCAGA CGGTTGAGGTTGGCTAATGTC 118 
Pex11β NM_0011069 CGCCTATTGATGGAACAAGAGACT TCCAGGTCCCACAGTTTCTACTC 106 
Pex11γ NM_026951.2 GACTCTGCTTGGTGGTGGA GCTCCGCAGCTTCTGTCTAA 111 
Pex14 NM_019781.2 GCCACCACATCAACCAACTG GTCTCCGATTCAAAAGAAGTCCT 97 
Pparα NM_011144.6 AGACCCTCGGGGAACTTAGA CAGAGCGCTAAGCTGTGATG 123 
Pparβ NM_011145.3 GCAGCCTCAACATGGAATGTC GAGCTTCATGCGGATTGTCC 116 
Pparγ NM_001127330.1 TTTTCAAGGGTGCCAGTTTC CATGGACACCATACTTGAGCA 128 
Sod1 NM_011434.1 GACCTGGGCAATGTGACTGCTG GCACCAGTGTACGGCCAATGATG 108 
α-Mhc NM_001164171.1 TGTGGTGCCTCGTTCCA TTTCGGAGGTACTGGGCTG 128 
β-Mhc NM_080728.2 ATGTGCCGGACCTTGGAAG CCTCGGGTTAGCTGAGAGATCA 170 
Nppa NM_008725.3 TCGTCTTGGCCTTTTGGCT TCCAGGTGGTCTAGCAGGTTCT 106 
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Nppb NM_008726.5 AAGTCCTAGCCAGTCTCCAGA GAGCTGTCTCTGGGCCATTTC 91 
Nppc NM_010933.5 CAGAAAAAGGGTGACAAGACTCC ATCCCAGACCGCTCATGGA 229 
Pdi NM_028944.3 GTACCGTTTGAGACCTCCTGTC CAACGAGTAGTCGTCCACTTCA 270 
Calreticulin NM_007591.3 AGTTTTGCTGTACTGGGCCT GCTTCTCTGCAGCCTTGGTA 139 
Col1a NM_007742.4 GTGTGATGGGATTCCCTGGACCTA CCTGAGCTCCAGCTTCTCCATCTT 126 
Col3a NM_009930.2 ACCCCCTGGTCCACAAGGATTA ACGTTCTCCAGGTGCACCAGAAT 151 
28S rRNA NR_003278.1 AAAGCGGGTGGTAAACTCCA   GGTTTCACGCCCTCTTGAAC 118 
Gapdh  NM_008084 TGGCAAAGTGGAGATTGTTGCC AAGATGGTGATGGGCTTCCCG 156 
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3.6.2. Biochemical experiments for protein abundance analysis 
Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western 
blotting are still widely used to separate and identity proteins based on molecular 
weight. After the transfer of the separated proteins to a membrane, the specific proteins 
are visualized using labeled antibodies (Yang and Mahmood, 2012). 
 
3.6.2.1. Preparation of heart tissue homogenates 
Heart tissue stored in liquid nitrogen was added to lysis solution (25 mM Tris-HCl, 1 
mM EDTA, 1 mM DTT, 250 mM sucrose, pH 7.8) containing 10% protease inhibitor 
mix M (SERVA, Heidelberg, Germany), and homogenized using an Ultra Turrax T25 
basic homogenizer for 30 s on ice. The homogenates were transfered in Eppendorf 
tubes and centrifuged at 1,000 g for 10 min at 4°C. The supernatants were stored at –
20°C. 
 
3.6.2.2. Preparation of whole cell lysates 
Cells in six-well plates were washed twice with PBS and 300 μl of cell lysis buffer (25 
mM Tris-HCl, 1 mM EDTA, 1 mM DTT, 250 mM sucrose, pH 7.8) containing 10% 
protease inhibitor mix M was added to each well. Cells were scraped thoroughly using 
a rubber scraper and lysed by pipetting before collection in Eppendorf tubes. After 
incubation on ice for 30 min with brief vortexting every 10 min, the samples were 
centrifuged at 1,000 g for 10 min at 4°C and the supernatants were collected and stored 
at –20°C. 
 
3.6.2.3. SDS-PAGE and Western blot 
Polyacrylamide gels containing SDS were prepared as shown in Table 22. The 
solutions used for western blot are listed in Table 23. The protein concentration of each 
sample was measured using the Bradford Assay with bovine serum albumin (BSA) as 
the standard (Bradford, 1976). SDS-PAGE was carried out using Bio-Rad 
electrophoresis apparatus. Homogenates of each sample were separated on a 12% 
polyacrylamide gel with 5 µl color-stained precision markers as size references. Protein 
transfer onto polyvinylidene difluoride (PVDF) membranes (Millipore, Schwalbach, 
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Germany) was carried out in a Bio-Rad tank. The membranes were blocked for 1 h at 
room temperature in blocking solution comprising 10% fat-free milk powder (Carl Roth, 
Karlsruhe, Germany) in Tris-buffered saline with Tween-20 (TBST). Primary antibodies 
were diluted in blocking solution and the membrane was incubated with antibody 
solution overnight at 4°C on a rotor shaker (Table 14). After washing with TBST (3 × 
10 min), membranes were incubated for 2 h with secondary antibodies. Bands were 
visualized using the Immunostar-AP detection kit (Bio-Rad) and exposed to BioMax 
MR films (Kodak, Stuttgart, Germany). Blots were stripped using stripping buffer (Table 
23) at 60°C for 60 min and redetected with other primary antibodies or control markers. 
 
Table 22.  Preparation of 1.5-mm 12% polyacrylamide gels containing SDS 
Buffer A 0.4% SDS 1.5 M Tris-HCl, adjusted to pH 8.8  
Buffer B 0.4% SDS, 0.5 M Tris-HCl, adjusted to pH 6.8   
Separating gel (12%)  2 ml ddH2O, 10 ml buffer A, 8 ml 30% acrylamide,15 μl 
TEMED, 130 μl 10% APS  
Stacking gel  5 ml  ddH2O, 5 ml buffer B, 1.25 ml 30% acrylamide, 15 
μl TEMED, 130 μl 10% APS  
10× loading buffer  3.55 ml ddH2O, 1.25 ml 0.5 M Tris-HCl (pH 6.8), 2.5 ml 
50% (w/v) glycerol, 2.0 ml 10% (w/v) SDS, 0.05% 
bromophenol blue, with 50 µl β-mercaptoethanol added 
before use 
 
Table 23. Composition of solutions used for western blots 
10×Electrophoresis 
buffer  
250 mM Tris, 2 M glycine, 1% SDS  
20× Transfer buffer  NuPAGE transfer buffer (Invitrogen, Heidelberg, 
Germany)  
10× TBS  0.1 M Tris, 0.15 M NaCl in ddH2O, adjusted to pH 8.0  
10% Blocking buffer  10 g fat free milk powder in 100 ml 1× TBST  
1× Washing buffer 
(TBST)  
10 mM Tris/HCl, 0.15 M NaCl, 0.05% Tween-20, pH 8.0  
Stripping buffer  62.5 mM Tris (pH 6.8), 0.2% SDS, 0.01% 
β-mercaptoethanol in ddH2O 
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3.6.3. Morphological methods 
3.6.3.1. Embedding of mouse heart tissue into paraffin 
Mice were anesthetized with 1.5% isoflurane and killed by cervical dislocation. The 
hearts of wild-type and Pex11α knockout mice were fixed by perfusion via the left 
ventricle with 4% Paraformaldehyde (PFA) in PBS (pH 7.4). The hearts were dissected 
and stored overnight in the same fixative solution (Table 24). Fixed hearts were 
embedded into paraffin (Paraplast Plus, St. Louis, MO) using a Leica TP1020 
embedding machine (3× 70%, 80%, 90% and 100% ethanol, each step for 90 min; 2× 
100% xylene each step for 90 min; 2× paraffin each step for 120 min). 
 
3.6.3.2. Hematoxylin and eosin staining of heart tissue 
Hematoxylin and eosin (H&E) staining is a routine histological staining method which 
we used for primary structural analysis and to evaluate the morphology of heart tissue. 
Hearts from wild-type and Pex11α knockout mice were immersion-fixed overnight in 4% 
PFA and embedded in paraffin as above, and 5 µm sections were prepared and 
incubated at 60°C overnight in a slide holder. The  sections were deparaffinized and 
rehydrated by immersing in 100% xylene (3× 10 min), followed by 2 min each in 99%, 
96%, 80%, 70% and 50% ethanol, and 2 min deionized H2O. The slides were then 
stained for 10 min at room temperature with hematoxylin (lot GHS3, Sigma-Aldrich), 
rinsed for 10 min under tap water to allow the blue stain to develop, and then immersed 
in eosin Y solution (lot MKBV9915v, Sigma-Aldrich) for 30 s. The samples were then 
dehydrated in 50%, 70%, 80% and 96% ethanol for 1 min each, then 2 min in 99% 
ethanol before mounting in DePeX (SERVA Electrophoresis GmbH) and drying 
overnight under a fume hood. 
 
3.6.3.3. Immunofluorescence staining of mouse hearts and HL-1 cells 
3.6.3.3.1. Immunofluorescence staining of mouse heart tissue 
The solutions used for immunofluorescence staining of heart tissue are listed in Table 
24. We prepared 2-µm sections using a Leica SM 2000 R rotation microtome. Sections  
deparaffinized and rehydrated as described above were digested with trypsin for 15 
min at 37°C to expose epitopes, blocked with 4% BSA for 1 h, and incubated with 
specific primary antibodies overnight at 4°C (Table 24). On the following day, the 
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sections were incubated with fluorophore-conjugated secondary antibodies (Table 14). 
Nuclei were counterstained with 2 µM TO-PRO-3 iodide for 10 min at room 
temperature (Thermo Fisher Scientific). The sections were analyzed by confocal laser 
scanning microscopy (CLSM) using a Leica TCS SP2 instrument.  
 
Table 24. Solutions used for immunofluorescence staining of heart tissue 
Fixative solution 4% PFA in 1× PBS (150 mM NaCl, 13.1 mM K2HPO4 , 
5 mM KH2PO4 ), pH 7.4 
10× PBS  1.5 M NaCl, 131 mM K2HPO4, 50 mM KH2PO4, pH 7.4 
Trypsin (0.1%)  0.1 g trypsin in 100 ml PBS, freshly prepared 
TEG buffer  5 mM EGTA, 0.1 M Tris, pH 9.0 
Blocking buffer (4% PBSA 
+ 0.05% Tween-20) 
8 g BSA and 100 μl Tween-20 dissolved in PBS to a 
final volume of 200 ml 
Dilution buffer (1% PBSA + 
0.05% Tween-20) 
2 g BSA and 100 μl of Tween-20 dissolved in PBS to a 
final volume of 200 ml  
 
 
3.6.3.3.2 Immunofluorescence staining of HL-1 cells 
Cardiomyocytes grown on fibronectin-coated coverslips were rinsed with PBS (pH 7.4) 
and fixed with 4% PFA in PBS for 20 min at room temperature. After fixation, cells were 
washed three times with PBS and incubated for 10 min in PBS containing 1% glycine, 
then 10 min in PBS containing 1% glycine and 0.1% Triton X-100 for permeabilization. 
After washing with PBS, cells were incubated for 30 min in PBS containing 1% BSA 
and 0.05% Tween-20. The coverslips were then incubated with primary antibodies 
overnight at 4°C in a moist chamber, followed by washing with PBS (3 × 5 min) and 
incubation with secondary antibodies for 1 h at room temperature. Nuclei were 
counterstained with 2 µM TO-PRO-3 iodide (Vijayan et al., 2011). The solutions used 
for immunofluorescence staining of HL-1 cells are listed in Table 25. 
 
 
 
Table 25. Solutions for immunofluorescence staining of HL-1 cells 
 51 
 
Fixative solution  4% PFA in PBS (150 mM NaCl, 13.1 mM 
K2HPO4 , 5 mM KH2PO4 ), pH 7.4  
Glycine (1%)  1 g Glycine in 100 ml PBS  
Glycine (1%) + Triton X-100 (0.3%)  1 g Glycine in 100 ml PBS and 0.3 ml Triton 
X-100  
Blocking buffer: 1% PBSA + 0.05% 
Tween-20  
2 g BSA in 200 ml PBS and 100 μl Tween-20  
Mowiol 4-88 solution  Add 16.7 % Mowiol 4-88 (w/v) into 80 ml of 
PBS then stir overnight to mix the solution, 
add additional 40 ml of glycerol, stir again 
overnight. Centrifuge at 15,000 U/min for 1h 
and take off the supernatant next day and 
store at -20°C for further use. 
Anti-fading agent (2.5%)  2.5 g N-propyl-gallate in 50 ml PBS and 50 
ml glycerol  
Mounting medium  Mowiol 4-88 mixed with anti-fading agent at 
a ratio of 3:1  
 
 
3.7. Statistical analysis  
Statistical analysis was carried out using GraphPad Prism v6.0 (Table 15). We used 
an unpaired Student’s t-test for comparisons between two values with one variant, and 
analysis of variance (ANOVA) for multi-group values with one variant, to evaluate the 
difference between and within experimental groups. Numerical data were presented 
as the mean ± standard deviation (SD). The data were visualized as bar diagrams, in 
which each column represents the mean value for three independent replicates for 
each group. The error bars represent the SD within each experimental group. The 
significance of the differences between the groups were indicated with the following 
symbols: *(P≤0.05), **(P≤0.01) and ***(P ≤0.001).  
 
 
 
  
 52 
 
4. Results 
4.1. Distribution of peroxisomes in the normal heart 
Little is known about the distribution and functionality of peroxisomes in the heart. 
There has been no systematic morphological analysis of peroxisomes in heart tissues 
or cardiomyocytes, and peroxisomal gene expression in the heart has not been 
examined in detail. However, such investigations could provide us with relevant 
information about the role of peroxisomes in the pathogenesis of heart diseases, and 
the impact of peroxisomal gene defects on heart functions. To address this knowledge 
gap, we first investigated the expression of genes encoding peroxisomal proteins in 
the heart and liver using in silico data, and we studied the distribution of peroxisomes 
in the heart tissues of adult wild-type mice by immunofluorescence microcopy.  
 
4.1.1. In silico expression levels of genes encoding peroxisomal biogenesis 
regulators, metabolic transporters, and enzymes in the heart and liver  
Expressed sequence tags (ESTs) are short, single-pass sequences of 200–500 bp, 
which can be used to characterize the transcripts expressed in specific tissues (Okubo 
et al., 1992). Data derived from EST sequencing in different tissues are stored in 
dbEST, and are extracted into UniGene. EST counts for each entry can therefore be 
used to estimate the relative expression levels of different genes in various tissues and 
organs calculated as a transcripts per million (TPM) value, which indicates the 
abundance of the corresponding mRNA (Wagner et al., 2012).  
The liver has the highest content of peroxisomes among mammalian organs (Islinger 
et al., 2010) and is therefore suitable as a positive control to evaluate peroxisome-
related gene expression and protein content in other organs. By comparing the TPM 
values in the UniGene library, we were able to compare the expression levels of all the 
genes listed in Fig. 4 in the mouse liver and heart. We found that the TPM values for 
Acox1, Acox2, Cat, Pparα and Pparγ were higher in the liver than the heart, whereas 
the opposite profile was observed for Acox3, Pex13, thiolase, Gnpat and Pparβ. This 
suggests there are differences in the metabolic activities of heart and liver peroxisomes. 
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Fig. 4. Transcript per million (TPM) values of genes encoding peroxisomal proteins in 
the mouse liver and heart. The TPM values were acquired from the UniGene database. Gene 
abbreviations: Pex: peroxin; Acox: peroxisomal acyl-coenzyme A oxidase; Cat: catalase; Sod: 
superoxide dismutase; Abcd: ATP binding cassette subfamily D; thiolase: 3-ketoacyl-CoA-
thiolase; Gnpat: glyceronephosphate O-acyltransferase; PPAR: peroxisome proliferator-
activated receptor. 
 
4.1.2. Genes encoding peroxisomal proteins are differentially expressed at the 
mRNA level in mouse ventricles and atria 
The data mining revealed that many peroxisome-related genes are expressed in the 
heart and that cardiomyocyte peroxisomes possess a specialized proteome that differs 
metabolically from liver peroxisomes. We therefore compared the expression of 
peroxisomal genes in different parts of the heart.  
The mRNA expression levels were determined by semi-quantitative RT-PCR in the left 
and right atria and ventricles of 10-week-old C57BL/J mice (Fig. 5). First, we 
determined the expression of three housekeeping genes (Gapdh, 28S rRNA and 
β-actin) in the four compartments to ensure a stable reference gene was available.  
Gapdh and 28S rRNA were more stably expressed in the different compartments than 
β-actin (Figure 5D) and we therefore retained Gapdh and 28S rRNA as housekeeping 
genes for PCR normalization. The semi-quantitative RT-PCR data revealed that most 
of the important genes encoding peroxisomal biogenesis proteins, membrane 
transporters and β-oxidation enzymes are expressed in the mouse heart, confirming 
the in silico findings. Interestingly, Pex5 and Pex6 were uniformly expressed in different 
compartments whereas Pex7 and Pex13 were expressed at higher levels in the 
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ventricles than the atria. The Acox1, Acox3, Gnpat, Aldp/Abcd1 and Cat genes showed 
heterogeneous expression levels among the four compartments but were generally 
expressed more strongly in the ventricles than the atria. Abcd4/Pmp69, Abcd3/Pmp70, 
Pmp24 and Pmp35 were uniformly expressed. 
 
Fig. 5. Genes encoding peroxisomal proteins are differentially expressed in mouse heart 
tissues. Total RNA from different parts of the heart was analyzed by semi-quantitative RT-
PCR to determine relative expression levels: (a) biogenesis genes, (b) peroxisomal membrane 
transporters (c) peroxisomal enzymes; (d) housekeeping genes (positive controls). 
Abbreviations: LA left atrium; RA right atrium; LV left ventricle; RV right ventricle; Pex peroxin; 
Acox peroxisomal acyl-coenzyme A oxidase; Cat catalase; Abcd ATP binding cassette 
subfamily D; Gnpat: glyceronephosphate O-acyltransferase; Pmp: peroxisomal membrane 
protein; 28S 28S rRNA.  
[Some of these data have been published as Figure 3 in Colasante, Chen, Ahlemeyer 
and Baumgart-Vogt, 2015] 
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The semi-quantitative PCR results indicated that most of the genes encoding 
peroxisomal proteins are differentially expressed among the compartments of the 
mouse heart. We therefore carried out qRT-PCR experiments to confirm these findings 
and generate quantitative expression profiles (Fig. 6). We found that Cat, Pex11 
(Pex11α, Pex11β and Pex11γ), Pex14, Sod1, Acox1, Pparα and Pparγ were 
expressed at significantly higher levels in the left ventricle than in other parts of the 
heart, whereas Pparβ and the Abcd1 were most strongly expressed in the left atrium. 
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Fig. 6. Quantitative real-time PCR analysis showing that some peroxisome-related 
genes are differentially expressed in mouse heart tissues. Total RNA from different heart 
compartments was analyzed to profile the expression of genes encoding peroxisomal 
biogenesis proteins, metabolic enzymes, membrane transporters and PPARs, with 28S rRNA 
as an internal standard to normalize the amount of mRNA. The columns show the mean ± SD 
for three experiments in each group, the mRNA expression of the left atrium (LA) was set to 1. 
Student’s t test was used to compare the LA value with each of the other compartments. [Some 
of these data have been published as Figure 3 in Colasante, Chen, Ahlemeyer and 
Baumgart-Vogt, 2015] 
 
4.1.3. The abundance of peroxisomal marker proteins differs among the four 
heart compartments 
The mRNA values reported above revealed the differential expression of genes 
encoding peroxisomal proteins among the four heart compartments, but differences at 
the mRNA level are not always translatable to changes in protein abundance. In order 
to determine the abundance of peroxisomal proteins directly, western blot analysis was 
carried out using specific antibodies against catalase, PEX13p and PEX14p. The 
results confirmed that catalase, PEX13p and PEX14p were indeed more abundant in 
the ventricles than in the atria (Fig. 7).  
 
 
Immunofluorescence analysis of formalin-fixed paraffin-embedded (FFPE) mouse 
heart tissue sections using antibodies against CAT, PEX14p and ABCD3 indicated that 
the abundance of these three proteins was higher in the ventricles than the atria (Fig. 
8). This experiment also showed that the ventricles contain significantly higher 
numbers of peroxisomes. 
Fig. 7. Catalase, PEX13p and PEX14p are 
more abundant in the ventricles than the 
atria. Comparative western blots of different 
heart compartments revealed differences in 
the levels of CAT, PEX13p and PEX14p. LA: 
left atrium, RA: right atrium, LV: left ventricle, 
RV: right ventricle [Published as Figure 3 in 
Colasante, Chen, Ahlemeyer and 
Baumgart-Vogt, 2015] 
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Fig. 8. Differences in the abundance of PEX14p, ABCD3 and CAT between the left 
ventricle and left atrium of the mouse heart. Immunofluorescence analysis of PEX14p, 
ABCD3 and CAT protein expression in the left atrium (LA) and left ventricle (LV) was carried 
out after fixing mouse hearts in 4% PFA. Scale bar: 25 µm. Primary antibody dilutions: PEX14p 
(1:4000), ABCD3 (1:1000), CAT (1:2000). [Published as Figure 3 in Colasante, Chen, 
Ahlemeyer and Baumgart-Vogt, 2015] 
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4.2. Developmental profile of peroxisome gene and protein expression 
There is limited information available about the dynamic behavior of peroxisome genes 
and proteins during mouse development, but our initial data mining (Section 4.1) 
provided evidence that peroxisomal gene expression changes during heart 
development in the mouse. A better understanding of such developmental changes 
could provide new insight to the role of peroxisomes in heart protection. We therefore 
analyzed the developmental profiles of genes encoding peroxisomal proteins and the 
proteins themselves in newborn and adult mice.  
First, we compared the hearts of 2-day-old and 8-week-old mice by semi-quantitative 
RT-PCR, revealing that Pmp2 and Pex6 are expressed at higher levels in the adult 
than in newborn animals, whereas the other genes are expressed at the same level 
regardless of age (Fig. 9). 
 
Next, we carried out qRT-PCR to determine the quantitative gene expression profiles 
of six peroxisomal genes. The expression levels of α-Mhc and β-Mhc, encoding the 
ventricular α-myosin and β-myosin heavy chains, are regulated by hormones and show 
opposing developmental profiles (Lompre et al., 1984). Accordingly, these genes are 
often used as markers for heart maturity, disease and stress, and we therefore used 
them as positive controls. As anticipated, the α-Mhc mRNA level was 2.2-fold higher 
Fig. 9. Semi-quantitative RT-PCR 
analysis of peroxisome-related and 
housekeeping gene expression in 
newborn (NB) and adult (A) mouse 
hearts. We analyzed the expression of 
peroxisomal biogenesis markers 
(Pex5, Pex6 and Pex7) and genes 
encoding membrane transporters 
(Pmp2, Pmp24, Pmp35, Abcd1, Abcd3 
and Abcd4) and enzymes (Acox1). 
The housekeeping gene β-actin was 
not suitable as a loading control, so 
28S rRNA was used instead. 
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in the adult heart compared to the newborn heart, whereas β-Mhc mRNA levels were 
significantly higher in the newborn heart than the adult heart (Fig. 10A,B). Interestingly, 
Cat, Pex11α and Acox1 were expressed at much higher levels in the adult heart than 
the newborn heart, whereas Sod1 showed the opposite profile, and Abcd3 and Pex14 
showed no significant differences regardless of age (Fig. 10C-H). This indicates that 
the genes encoding peroxisomal proteins are regulated individually and not in concert 
as the heart ages. 
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Fig. 10. Analysis of α-Mhc, β-Mhc, Cat, Pex14, Pex11α, Abcd3 and Acox1 expression in 
the newborn and adult heart by qRT-PCR. Total RNA was isolated from 2-day-old (P2) and  
8-week-old (8W) mouse hearts, and 28S rRNA was used as an internal standard. The columns 
represent the mean ± SE of four experiments in each group. The expression level at P2 was 
set to 1, and Student’s t-test for unpaired values was used to compare the relative levels in the 
adult and newborn hearts. 
 
Next, the abundance of selected peroxisomal proteins was analyzed by western blot, 
revealing differences between the newborn and adult mouse in the abundance of 
catalase and PEX14p (Fig. 11). Catalase was much more abundant in the adult heart, 
whereas PEX14p was more abundant in the newborn heart.  
 
Fig. 11. Abundance of the peroxisome biogenesis protein PEX14p and the enzyme 
catalase as the heart ages. Western blot analysis of PEX14p and catalase in newborn (NB) 
and adult (A) whole heart homogenates, based on 15 µg total protein loaded in each lane. The 
membrane was probed using anti-PEX14p, anti-Cat and anti-GAPDH antibodies.  
 
4.3. Pex11α and Pex14 expression in ischemia-reperfusion hearts 
It is unclear whether peroxisomes, and in particular the peroxisome-related genes and 
proteins discussed above, play a role in the hypoxia injury induced by heart attack. We 
therefore investigated the expression of these genes and proteins in the ischemia-
reperfusion rat model, a powerful tool for the study of heart function at the molecular 
level and an enduring model for ischemia-reperfusion injury.  
The following experiments were carried out in collaboration with Professor Böning 
(Department of Cardiovascular Surgery, University Hospital Giessen and Marburg, 
Campus Giessen, Giessen, Germany), who kindly provided the rat samples. The rat 
heart ischemia-reperfusion model used in this study involved two steps: (1) ischemia 
for 90 min induced by aortic clamping, and (2) subsequent reperfusion for 90 min. The 
heart was exposed to intervention for less than 4 h before storage at –80°C.  
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Quantitative real-time PCR was carried out using cDNA isolated from the ischemia-
reperfusion heart and an untreated control to determine the expression mRNAs for the 
2 peroxin proteins of  PEX11α and PEX14, thus providing evidence for the effect of 
ischemia-reperfusion injury on peroxisome biogenesis. Interestingly, Pex11α 
expression was significantly downregulated in the ischemia-reperfusion heart 
compared to the control group, whereas there was no difference in Pex14 expression 
(Fig. 12). 
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Fig. 12. Pex11α and Pex14 expression in ischemia-reperfusion (IR) hearts and normal 
control (NC) hearts. Left ventricular tissue was kindly provided by Prof. Böning. Total RNA 
was isolated and 2 µg was used to prepare cDNA for qRT-PCR analysis of Pex11α and Pex14 
expression, with 28S rRNA as an internal standard to normalize the amount of mRNA. The 
columns represent the mean ± SE for three experiments in each group. The expression level 
in the control hearts was set to 1, and Student’s t-test for unpaired values was used to 
determine the relative expression levels in the ischemia-reperfusion hearts. 
 
To confirm the relevance of the gene expression levels, we measured the abundance 
of PEX14p in the same experimental model. Antibodies that differentiate between the 
three isoforms of PEX11 are not yet available, so we were unable to confirm the qRT-
PCR results for Pex11α at the protein level. Interestingly, the western blot data for 
PEX14p contradicted the qRT-PCR results and revealed that the protein was more 
abundant in the left ventricle of the ischemia-reperfusion hearts than the controls, 
whereas PEX3p was more abundant in the control hearts than the ischemia-
reperfusion model (Fig. 13). ABCD3 and catalase showed no significant difference in 
abundance between the two groups (Fig. 13). 
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Fig. 13. Abundance of peroxisome-related proteins in ischemia-reperfusion (IR) rat 
hearts and normal controls. A. Total protein homogenates were prepared from the left and 
right ventricular heart tissue of control rats and an ischemia-reperfusion group. Anti-CAT, anti-
PEX13p, anti-PEX14p and anti-ABCD3 antibodies were used to detect the proteins by western 
blotting. B. Coomassie Brilliant Blue staining was used to ensure equal gel loading.  
 
4.4. Peroxisomal characteristics in the hearts of Pex11α knockout mice 
The strong downregulation of Pex11α gene expression in the ischemia-reperfusion 
model indicated that ischemia-reperfusion injury may affect peroxisome biogenesis 
and fission by reducing the levels of PEX11α. We therefore tested the Pex11α general 
knockout mouse model (X. Li, Baumgart, et al., 2002) to investigate whether the loss 
of this protein influences the functionality of the heart. The development and partial 
characterization of the Pex11α knockout mouse has been described (Li et al., 2002). 
 
4.4.1. The phenotype of the Pex11α knockout mouse line 
As previously reported, the Pex11α knockout mouse line showed no major observable 
differences in phenotype compared to wild-type mice (Li et al., 2002).  
 
4.4.2. Body and heart weight of the Pex11α knockout mice 
We measured the total body weight and heart weight of age-matched (8–10 weeks) 
Pex11α knockout and wild-type mice, revealing no differences in either parameter (Fig. 
14). This suggested the absence of a macroscopic phenotype in the hearts of the 
Pex11α knockout mice. 
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Fig. 14. Total body weight and heart weight of the Pex11α knockout mice and wild-type 
mice. The body weight (A) and heart weight (B) of Pex11α knockout mice and wild-type mice 
were recorded at the same age (8 weeks). The columns represent the mean ± SE for five mice 
in each experimental group. Student’s t-test for unpaired values was used to compare the 
values from each group. 
 
4.4.3. H&E staining of wild-type and Pex11α knockout mouse heart tissue 
To determine whether the absence of the Pex11α gene affected the ultrastructure of 
the cardiomyocytes, paraffin-embedded sections of wild-type and Pex11α knockout 
hearts were compared by histological staining with H&E. There were no obvious 
differences in cellular morphology or structure between the two groups (Fig. 15).  
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Fig. 15. Morphological comparison of wild-type (WT) and Pex11α knockout (KO) mouse 
heart tissues. H&E staining of PFPE heart tissue revealed no differences in histology. Images 
were captured using a Leica DMRD fluorescence microscope equipped with a Leica DC 480 
camera. Scale bar: 25 µm. 
 
4.4.4. Abolishing Pex11α expression induces genes encoding peroxisome-
related proteins and PPARs in the mouse heart 
To investigate whether the Pex11α knockout induced changes in peroxisome-related 
gene expression, qRT-PCR was used to compare the hearts from wild-type and 
Pex11α knockout mice. This experiment confirmed the absence of Pex11α mRNA in 
the knockout mice (Fig. 16A). Interestingly, whereas Pex11γ was expressed at the 
same level in both lines, Pex11β was significantly induced in the Pex11α knockout 
mice. Pex7 and Acox1 were also induced in the Pex11α knockout line, whereas Pex5, 
Cat, Acox2 and Acox3 showed no significant differences. Furthermore, the loss of 
Pex11α also resulted in a slight but non-significant increase in Pparβ expression 
(1.6-fold, P˃0.05) and a significant increase in Pparγ expression (2.9-fold, P< 0.01), 
suggesting a peroxisome-based PPAR-feedback loop (Fig. 16J-L).  
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Fig. 16. The knockout of Pex11α increases the expression of certain peroxisome-related 
genes and PPARs in the mouse heart. Total RNA was isolated from the left ventricle of wild-
type (WT) and Pex11α knockout (KO) mice for the analysis of peroxisome- related and PPAR 
genes. The columns represent the mean ± SE of three mice in each experimental group. 
Student’s t-test for unpaired values was used to compare the Pex11α knockout mice with the 
corresponding wild-type group. 
 
4.4.5. Pex11α knockout animals display abnormal peroxisome morphology 
Immunofluorescence staining of mouse hearts showed that the morphology of the 
peroxisomes in the Pex11α knockout line is abnormal. Both the size and the number 
of peroxisomes increased in the knockout mice compared to wild-type controls. The 
peroxisomes in the Pex11α knockout hearts were much bigger, irregular in shape, and 
some adopted an unusual ring-like structure (Fig. 17). 
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Fig. 17. Immunofluorescence staining of wild-type and Pex11α knockout mouse hearts 
using antibodies against PEX14p, ABCD3 and CAT. Mouse heart tissue was fixed in 4% 
PFA and embedded in paraffin before 2-µm sections were prepared for immunofluorescence 
staining. The primary antibodies were diluted as follows: PEX14p (1:4000), ABCD3 (1:1000), 
CAT (1:2000). [Published as Fig. 4 in Colasante, Chen, Ahlemeyer and Baumgart-Vogt, 
2015] 
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4.4.6. Effect of Pex11α knockout on the abundance of peroxisomal proteins  
Next we determined the abundance of selected peroxisomal proteins by western blot 
in the Pex11α knockout and wild-type lines, revealing the presence of higher levels of 
catalase and PEX14p in the hearts of Pex11α knockout mice (Fig. 18). 
 
Fig. 18. Abundance of catalase and PEX14p in Pex11α knockout and wild-type mouse 
hearts. Western blot analysis was used to compare the abundance of peroxisomal proteins in 
the homogenates of hearts from wild-type, homozygous Pex11α knockout and heterozygous 
mice. [Published as Fig. 4 in Colasante, Chen, Ahlemeyer and Baumgart-Vogt, 2015] 
 
4.4.7. Catalase activity in the Pex11α knockout heart homogenates  
We observed no difference in Cat expression between the hearts of Pex11α knockout 
and wild-type mice, but the protein was more abundant in the knockout line. We 
therefore carried out a catalase assay to confirm that the protein abundance 
corresponded to higher enzymatic activity in the Pex11α knockout mouse. Due to the 
limited number of animals, it was not possible to carry out statistical analysis of the 
results. However, we observed a clear increase in catalase activity in the knockout line 
(Fig. 19). 
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Fig. 19. The specific activity of catalase in the hearts of Pex11α knockout and wild-type 
mice. Left ventricular tissue homogenates from three wild-type (WT) mice and three Pex11α 
knockout (KO) mice were used to measure catalase activity (kU/L). Four of the six mice in 
these experiments were 8-week-old male mice and the other two were 11-week-old female 
mice. The results therefore cannot be analyzed statistically and are shown in descriptive form 
only.  
 
4.4.8. Cardiac-specific genes are modulated in the Pex11α knockout line 
Quantitative RT-PCR revealed the disrupted expression of many typical cardiac 
marker genes. For example, α-Mhc (predominant in the normal adult heart) and β-Mhc 
(predominant in the neonatal heart) were both expressed at much lower levels in the 
Pex11α knockout line. Furthermore, Nppc (encoding CNP) was downregulated in the 
Pex11α knockout line but Nppb (encoding BNP) was upregulated and Nppa (encoding 
ANP) was unaffected. The endoplasmic reticulum markers PDI and Calreticulin 
showed no differences in expression in the hearts of the wild-type and knockout mice, 
and similar results were observed for the extracellular matrix and pro-fibrotic markers 
Col1a and Col3a (Fig. 20). 
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Fig. 20. Modulation of cardiac-specific genes in the hearts of Pex11α knockout mice. 
Total RNA was isolated from the hearts of wild-type (WT) and Pex11α knockout (KO) mice for 
the qRT-PCR analysis of cardiac-specific genes, using 28S rRNA as an internal control. The 
columns represent the mean ± SE for three mice in each experimental group. Student’s t-test 
for unpaired values was used to compare the Pex11α mice with the corresponding wild-type 
control group.  
 
4.4.9. Mitochondria are affected by oxidative stress in the Pex11α knockout line 
The loss of peroxisomal biogenesis proteins induces severe oxidative stress in many 
cell types due to the primary loss of peroxisomal function and the secondary effect on 
mitochondria (Baumgart et al., 2001). SOD2 is often used to monitor the upregulation 
of antioxidant enzymes in cells with peroxisomal deficiency, so we compared the 
abundance of this protein in the hearts of wild-type and Pex11α knockout mice. We 
found that SOD2 was more abundant in the Pex11α knockout line, confirming the 
elevation of oxidative stress in the heart mitochondria (Fig. 21). 
 
 
Fig. 21. SOD2 protein is more abundant in the hearts of Pex11α knockout mice than 
wild-type controls. Cleared homogenates prepared from the left ventricles of wild-type (WT) 
and Pex11α knockout (KO) mice were compared by loading 15 µg total protein in each lane 
and staining the gels using antibodies specific for SOD2 and thereafter GAPDH.  
 
4.4.10. Shortening capacity of Pex11α knockout cardiomyocytes  
The modulation of cardiac markers in the Pex11α knockout line suggested there may 
be an impact on the physiological function of isolated cardiomyocytes. We therefore 
measured the cell shorting capacity of isolated cardiomyocytes from each line, 
revealing no significant differences in cell shortening parameters. We subjected the 
cardiomyocytes to stress by treating them with the catalase inhibitor 3-amino-1,2,4-
triazole (3-AT), which inhibited the cell shortening capabilities equally in both groups 
(P < 0.01, Fig. 22A). However, the percentage of cell shortening in the Pex11α 
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knockout cardiomyocytes after 3-AT treatment was significantly larger than that of the 
wild-type cardiomyocytes (Fig. 22B-D).  
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Fig. 22. The cell shortening performance of wild-type and Pex11α knockout mouse 
cardiomyocytes. Primary cardiomyocytes were isolated from the ventricles of wild-type (WT) 
and Pex11α knockout (KO) mice, and cell shortening was measured. The columns represent 
the mean ± SE for four mice in each experimental group. Student’s t-test for unpaired values 
was used to compare the values recorded for Pex11α cardiomyocytes with the corresponding 
wild-type control group, or the treatment group with the non-treatment group.  
 
4.4.11. H&E staining and cardiomyocyte counting in wild-type and Pex11α 
knockout heart tissues following ischemia-reperfusion injury 
The results summarized above indicated no significant difference in the morphology of 
wild-type and Pex11α knockout hearts under normal conditions. We therefore 
examined the same parameters following ischemia-reperfusion injury, and found that 
a significantly larger number of cells in the Pex11α knockout hearts suffered injury-
induced damage compared to wild-type hearts (P<0.01, Fig. 23).  
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Fig. 23. Figure legend on page 76 
Fig. 23. H&E staining (A) and cell counting (B) of cardiomyocytes in the hearts of wild-
type and Pex11α knockout mice after ischemia-reperfusion injury. Heart tissue was fixed 
in 4% PFA and embedded in paraffin, and 5-µm sections were stained with H&E. All cells in 
each slide were counted, and broken cells were noted. All together 500 hundred cells were 
used for each group. The columns represent the mean ± SE for four mice in each experimental 
group. Student’s t-test for unpaired values was used to compare the values from Pex11α mice 
with the corresponding wild-type control group (Scale bar: 50 µm and 15 µm).  
 
4.5. HL-1 cells as a model to study functional cardiac alterations induced 
by peroxisomal dysfunction  
To reduce the number of animal experiments, the model cell line HL-1 was used to 
analyze the effects of peroxisomal alterations on cardiomyocyte functions and 
signaling pathways. 
 
4.5.1. HL-1 cells grew best in flasks coated with 0.1% gelatin 
Before commencing detailed experiments, we established the optimal growth 
conditions for HL-1 cells on coated coverslips. HL-1 cells grow rapidly using the precise 
conditions and medium described by the Claycomb group. All culture flasks must be 
coated before cell seeding, and we tested several different materials and coating 
methods. We found that cells grew better on a plastic surface than on glass coverslips, 
and that 0.1% gelatin and fibronectin in gelatin were both suitable for coating, with 
neither showing toxicity or negative effect on cellular morphology. 
 
 
 
Fig. 24. Morphology of HL-1 cells 
growing on coated surfaces. HL-1 cells 
were cultured in six-well plates treated 
with different coating materials overnight 
(ploy-L-lysine, collagen I, 0.1% gelatin, 
and fibronectin in gelatin). Cells were 
observed by light microscopy 48 h after 
seeding.  
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4.5.2. Most peroxisome-related genes are expressed in HL-1 cardiomyocytes 
The establishment of the HL-1 cell line was followed by many physiological and 
molecular studies (Nguyen et al., 1999; White et al., 2004; Wondergem et al., 2012). 
As a tumor cell line, it is still a matter of debate whether HL-1 cells possess the 
characteristics of in vivo atrial cardiomyocytes. Therefore, we investigated whether 
peroxisomal genes were expressed at sufficient levels for analysis by comparing them 
with the source tissue (mouse left atrium). Although we confirmed the expression of all 
the peroxisomal genes in HL-1 cells, the levels differed from mouse left atrium tissue. 
Cat and Abcd1 were expressed at a lower level in the HL-1 cells than in the mouse left 
atrium, whereas Sod1 and Pex14 showed the opposite profile. The Pex11 family was 
also expressed in the HL-1 cells. Pex11α expression was lower in the cells than in vivo, 
whereas Pex11β was expressed at similar levels in both, and Pex11γ was strongly 
elevated in the cells. Interestingly, the largest discrepancy was found in the PPAR 
family: Pparα and Pparγ were hardly expressed in HL-1 cells, whereas Pparβ was 
expressed at approximately the same level in the HL-1 cells and the mouse atrium 
tissue (Fig. 25). 
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Fig. 25. Comparative expression of genes encoding peroxisomal proteins and PPARs 
in the HL-1 cell line and left atrium of the mouse heart. Total RNA was isolated from HL-1 
cells and left atrium tissue for qRT-PCR analysis using primers for peroxisomal markers and 
PPARs, with 28S rRNA as an internal control. The columns represent the mean ± SE for three 
mice in each experimental group. Student’s t-test for unpaired values was used to compare 
the values for HL-1 cells with the atrial tissue. 
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4.5.3. Potential methods to induce catalase: ethanol treatment and catalase 
overexpression 
Alcohol consumption is a risk factor in many heart diseases (Djoussé et al., 2008). 
Catalase is induced in rats fed on an ethanol-rich diet (Fahimi et al., 1979). However, 
the mechanism by which alcohol influences the heart remains unclear and its response 
is not well understood. To investigate the protective function of peroxisomes under 
stress conditions, we treated HL-1 cells with 0.5% ethanol for 72 h, revealing a 4.5-fold 
increase in Cat mRNA levels (see Fig. 26A) and also an increase in the abundance of 
catalase protein (Fig. 26B). We also observed a 2.3-fold increaser in catalase activity 
in the ethanol-treated group (P<0.05, Fig 26C).  
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Fig. 26. The induction of catalase by ethanol. Cat mRNA levels (A), the abundance of 
catalase protein (B), and catalase activity (C) were higher in HL-1 cells treated with 0.5% 
ethanol. HL-1 cells were cultured in six-well plates pretreated with fibronectin in gelatin 
overnight. When they had reached 50% confluence, the cells were treated with 0.5% ethanol 
for 72 h. Total RNA was isolated for qRT-PCR analysis using Cat gene-specific primers and 
28S rRNA as an internal control. Western blots and catalase activity assays were carried out 
using total cell homogenates. The columns represent the mean ± SE for three experiments in 
each group. The Cat mRNA level in the control group was set to 1, and Student’s t-test for 
unpaired values was used to compare the ethanol-treatment group with the control group. 
B. 
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4.5.4. The effect of Pex14 knockdown on HL-1 cells 
4.5.4.1. Establishment of the Pex14 siRNA knockdown model  
HL-1 cells are difficult to transfect and various transfection reagents were tested with 
little success (data not shown) until Lipofectamine 3000 reagent was used, resulting in 
satisfactory performance and reproducibility. At the mRNA level, we achieved a 
knockdown efficiency of ~90% (i.e., 10% of normal Pex14 mRNA levels) after 6 days, 
corresponding to a dramatic decrease in PEX14p protein abundance (Fig. 27). 
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Fig. 27. The expression of Pex14 mRNA and PEX14p was significantly diminished in HL-
1 cells transfected with Pex14 siRNA. HL-1 cells were cultured in six-well plates coated with 
fibronectin and gelatin at starting concentrations of 1.5–2 × 105 per well. Attachment was 
observed 4–6 h after seeding, and the cells were then transfected by adding 10 µl of 
Lipofectamine 3000 reagent and 150 pmol of Pex14 siRNA into each well. After 6 days, cells 
were harvested and total RNA was isolated for PCR, and total protein was isolated for western 
blot analysis. The columns represent the mean ± SE for three experiments in each group. The 
average value for the control group was set to 1, and Student’s t-test for unpaired values was 
used to compare the knockdown cells (treated with Pex14 siRNA) to the control group (treated 
with Scramble siRNA). 
 
4.5.4.2. Pex14 siRNA knockdown induces catalase but does not affect the 
mitochondrial marker SOD2 in HL-1 cardiomyocytes 
Knockdown of the peroxisomal biogenesis protein PEX14 disrupts peroxisomal matrix 
protein import, which leads to severe oxidative stress in many cell types due to primary 
peroxisomal and secondary mitochondrial dysfunction (Baumgart et al., 2001; 
Ahlemeyer et al., 2012). Catalase and SOD2 are often used to monitor the upregulation 
A. B. 
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of antioxidant enzymes in cells with peroxisomal deficiency. Accordingly, we found that 
Cat was upregulated 2.4-fold in the Pex14 knockdown group (P < 0.05) and the 
catalase protein was also more abundant in these cells, as confirmed by western blot. 
There was no difference between the knockdown and control cells in terms of the 
mitochondrial marker SOD2 or cell viability as determined by the MTT assay, which 
partly reflects mitochondrial function (Fig. 28). 
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Fig. 28. The effect of Pex14 siRNA knockdown on catalase and mitochondrial markers 
in HL-1 cardiomyocytes. Pex14 siRNA knockdown induces Cat gene expression (A) and 
increases the abundance of catalase protein (B) but does not affect the mitochondrial marker 
SOD2 (B) or cell viability (C). After 6 days of exposure to Pex14 siRNA, total RNA and total 
protein were isolated from HL-1 cells for RT-PCR and western blot analysis, respectively, or 
cells were directly used in the MTT assay. The columns in A and C represent the mean ± SE 
for three experiments in each group. The average value of the control group was set to 1, and 
Student’s t-test for unpaired values was used to compare the knockdown cells (treated with 
Pex14 siRNA) to the control group (treated with Scramble siRNA). 
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4.5.4.3. Pex14 siRNA knockdown modulates the expression of cardiac markers  
The effect of Pex14 knockdown in HL-1 cardiomyocytes has not been reported thus 
far, so it was important to determine the expression profiles of cardiac markers. We 
observed the downregulation of Nppa and the upregulation of Nppb (although the 
sample numbers were not sufficient to test statistical significance) and the expression 
profile of Nppc did not change. Interestingly, α-Mhc (predominant in the adult heart) 
was strongly suppressed (83.3-fold) in the Pex14 knockdown cells, whereas β-Mhc 
(which inhibits cardiomyocyte contractile function) was upregulated 1.8 fold (Fig. 29). 
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Fig. 29. Cardiac markers are modulated in Pex14 knockdown HL-1 cells. After 6 days of 
exposure to Pex14 siRNA, total RNA was isolated from HL-1 cells for the analysis of Nppa, 
Nppb, Nppc, α-Mhc and β-Mhc expression by RT-PCR. The columns represent the mean ± 
SE for three experiments in each group. The average value of the control group was set to 1, 
and Student’s t-test for unpaired values was used to compare the knockdown cells (treated 
with Pex14 siRNA) to the control group (treated with Scramble siRNA). 
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4.5.4.4. Pex14 siRNA knockdown inhibits HL-1 cell proliferation 
The total number of HL-1 cells and the proportion of dead cells were determined after 
transfection with Pex14 siRNA to investigate the effect of Pex14 knockdown on cell 
proliferation. Following the Pex14 siRNA treatment, the total cell number was lower 
than the Scramble siRNA control group, but the proportion of dead cells was higher 
(Fig. 30).  
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Fig. 30. Pex14 siRNA knockdown inhibits the proliferation and viability of HL-1 cells. 
After 6 days of exposure to Pex14 siRNA, cells were harvested and stained with trypan blue. 
The total cell number in each group was determined, and the proportion of dead cells was 
calculated. The columns represent the mean ± SE for three experiments in each group. The 
average total cell number of the control group was set to 1, and Student’s t-test for unpaired 
values was used to compare the knockdown cells (treated with Pex14 siRNA) to the control 
group (treated with Scramble siRNA). 
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5. Discussion 
5.1. Overview of the thesis 
The scientific literature provides little information about the role of peroxisomes in the 
heart. We therefore studied the characteristics of peroxisomes in cardiomyocytes to 
gain insight into their metabolic role, and particularly the effect of peroxisome 
dysfunction in cultured HL-1 cardiomyocytes and whole heart tissues. We observed 
the heterogeneous distribution of peroxisomes in different heart tissues as well as 
variations in peroxisomal enzyme composition, with the greatest abundance of 
peroxisomes in the left ventricle. Peroxisome-related gene expression and protein 
abundance changed during heart development. The analysis of Pex11α knockout mice 
and Pex14 knockdown cardiomyocytes indicated that peroxisomal dysfunction 
affected the expression of typical cardiac marker genes, suggesting that peroxisomal 
metabolic activity is necessary to maintain cardiac homeostasis and protect cardiac 
functions. 
 
5.2. Part I: Functional characterization of peroxisomes in the mouse heart 
5.2.1. The expression of genes encoding peroxisomal proteins in the mouse 
heart  
The protective role of peroxisomes in the heart is well established (Fahimi et al., 1979). 
The antioxidant activity of catalase, an abundant peroxisomal enzyme, explains part 
of this protective effect, but the full nature of the protective activity and its regulation 
are not clearly understood. 
The in silico analysis of EST data allowed us to compare the expression of peroxisome-
related genes in the heart and liver. However, the in silico comparison of EST data can 
only provide an approximate expression profile because the indicated values are 
mostly based on sequencing data from single animals. The values do not provide 
accurate expression levels in each organ, but at least show whether a gene is 
expressed or not and give some rough indication of relative expression levels in 
different tissues (Nagaraj et al., 2007). The data retrieved by database mining revealed 
that many important peroxisomal genes are expressed at detectable levels in the 
mouse heart. The liver has the highest content of peroxisomes among mammalian 
organs (Baumgart, 1997; Völkl et al., 1999), so the differential expression of 
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peroxisomal genes between the heart and liver offered a reflection of their specialized 
metabolic functions. Our results, showing that the Cat gene encoding catalase is 
expressed more strongly in the liver than the heart, support earlier studies reporting 
that the catalase activity per gram of heart tissue is about 2% of liver catalase activity 
in rats and mice (Y. Chen et al., 1994; Doroshow et al., 1980). 
The metabolic activity of the liver generates abundant ROS (Jaeschke and 
Ramachandran, 2011) and therefore requires large amounts of catalase to degrade 
these harmful molecules and to protect the hepatocytes (DeJong et al., 2007). The 
liver is also the main organ for detoxification and oxidative management (Dunning et 
al., 2013). Importantly, the liver metabolizes diverse fatty acids, and this process takes 
place in both mitochondria and peroxisomes. However, the spectrum of fatty acids that 
peroxisomes can degrade is much wider than the capabilities of the mitochondria, 
including LCFAs, VLCFAs, methyl branched chain fatty acids, prostaglandins, 
polyunsaturated fatty acids (PUFAs), leukotrienes and toxic lipid intermediates 
(Colasante et al., 2015). In contrast, the heart uses fatty acids mainly for the production 
of energy via mitochondrial β-oxidation. This is reflected by the results of our in silico 
analysis, which showed that genes involved in fatty acid transportation (Abcd3) and 
peroxisomal β-oxidation (Acox-1 and Acox-2) are more strongly expressed in the liver 
than the heart.  
Interestingly, the Gnpat gene encoding glyceronephosphate O-acyltransferase, which 
is essential for the initiation of ether phospholipid (plasmalogen) biosynthesis in 
peroxisomes (Wanders and Waterham, 2006), was more strongly expressed in the 
heart than the liver. Plasmalogens are membrane-localized antioxidants that prevent 
lipid peroxidation. They are highly enriched in the heart and are necessary to maintain 
functional cellular membranes (Braverman et al., 2012; Lessig and Fuchs, 2009).  
In conclusion, the difference between metabolic functions in the heart and liver is 
reflected by the expression profiles of genes encoding peroxisome-related proteins. 
 
5.2.2. Selection of housekeeping genes and protein loading controls for the 
analysis of heart tissue 
An appropriate internal standard is necessary for the quantitative analysis of PCR and 
western blot data. Common RNA internal standards include glyceraldehyde-3-
 85 
 
phosphate dehydrogenase (GAPDH), β-actin and 28S rRNA because their expression 
levels are relatively constant under different experimental conditions (Zhong and 
Simons, 1999). We tested several internal controls to determine their suitability and 
found some interesting differences in expression that narrowed our selection.  
GAPDH, a key enzyme which catalyzes the sixth step in the glycolysis pathway, is 
expressed at high levels in mouse and human skeletal and heart muscle (Piechaczyk 
et al., 1984). It is often used as a protein loading control for western blots and as an 
internal control for RT-PCR. Because glycolysis readily responds to environmental 
changes and intracellular metabolic demands, it was unclear whether GAPDH would 
be suitable as a control for the analysis of the heart, which is greatly affected by 
metabolic fluctuations. However, we found that Gapdh mRNA and GAPDH protein 
levels remained stable, allowing its use as a marker for the comparison of peroxisome 
related mRNA and protein levels in different parts of the heart. In fetal and adult mouse 
hearts, GAPDH was more stable than the other internal controls, including β-actin.  
The 18S and 28S ribosomal RNAs make up 80% of a total RNA sample and are 
unlikely to fluctuate under conditions that affect the expression of mRNAs (deLeeuw 
et al., 1989). Under hypoxic conditions, 28S rRNA was a reliable internal control for 
the comparative analysis of transcription (Zhong et al., 1999). Accordingly, we also 
found that 28S rRNA was suitable as an internal control, although it can only be used 
for the analysis of RNA samples and GAPDH was required for proteins. 
Actin and tubulin are also widely used as loading controls for western blots and PCR 
analysis, but many studies have reported differential expression in animal tissues and 
cultured cells (Eaton et al., 2013; Suzuki et al., 2011; Wishart et al., 2008). Similarly, 
we observed the unequal distribution of β-actin in different parts of the heart and at 
different developmental stages, so this marker was not used in our experiments.  
 
5.2.3. Genes related to peroxisome biogenesis and metabolism are differentially 
expressed in the four heart chambers 
The heart is a muscular organ with four chambers: two atria and two ventricles 
(Zimmerman, 1966). The ventricles have thicker walls than the atria and the 
cardiomyocyte organization is also compartment-specific, reflecting their different 
functions (Simek et al., 1995). These functional differences are reflected in the gene 
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expression and metabolic activity of each chamber, although these aspects have not 
been characterized in detail (Barth et al., 2005).  
Previous studies of peroxisomes in the heart were restricted to the left ventricle, using 
catalase as the only marker (Hand, 1974; Herzog et al., 1974; Oberley et al., 1990). 
The experiments presented herein are the first to use peroxisome-related markers to 
demonstrate significant differences in peroxisome-related gene expression, 
peroxisomal protein abundance and peroxisome number in the four heart chambers. 
PCR, western blot and immunofluorescence analysis provided concordant data 
showing that peroxisome-related mRNAs and proteins are more abundant in the 
ventricles than the atria, and that the left ventricle (which has the highest workload) is 
particularly enriched for peroxisomal enzymes and mRNAs. 
In summary, these observations provide the first evidence that the functional and 
anatomical differences between the atria and ventricles are reflected by the expression 
of peroxisome-related genes and the abundance of peroxisomal proteins. Within the 
heart, peroxisomal activity appears to be modulated to adjust to the various metabolic 
requirements and workloads of the four heart chambers. 
 
5.2.4. Developmental profiles of peroxisomal gene expression  
5.2.4.1. Energy conversion and ROS metabolism during heart development  
The substrates for metabolism and energy generation in the heart change substantially 
during the transition from fetal to postnatal development (Carley et al., 2014). The fetal 
heart utilizes mainly carbohydrates as the primary energy source (Wittels and Bressler, 
1965) whereas LCFAs are the principal metabolic fuel of the adult heart (Carlsten et 
al., 1961; Shipp, 1964). After birth, there is a rapid switch from carbohydrate to fatty 
acid utilization.  
The newborn heart is more susceptible to oxidative stress and ischemia-reperfusion 
injury than the adult heart (Cabigas et al., 2012). One important reason for ischemia-
reperfusion injury is the noxious effects of ROS (Kalogeris et al., 2014). The 
accumulation of ROS leads to apoptosis, inflammation and changes in the profile of 
contractile proteins in the heart (Cabigas et al., 2012).  
Despite the link between fatty acid and ROS metabolism in peroxisomes, there is little 
information available about the function of these organelles during postnatal 
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development in the heart. Therefore, we compared peroxisome-related gene 
expression in the hearts of newborn and adult mice to identify peroxisomal proteins 
that change in abundance during heart development.  
 
5.2.4.2. Potential protective function of peroxisomes during heart maturation 
Peroxisomes are involved in the maturation of many organs. Earlier studies conducted 
by the Baumgart-Vogt group have shown that hepatoblastoma and osteoblast 
differentiation is accompanied by an increase in the expression of peroxisome-related 
genes and the abundance of the corresponding proteins (Qian et al., 2015; Stier et al., 
1998). Our results indicate that heart development may also involve the proliferation 
of peroxisomes to establish the β-oxidation pathway and antioxidant activity. We found 
that the peroxisomal biogenesis markers Pex6 and Pex11α, the membrane transporter 
gene Pmp2, and genes related to the β-oxidation pathway (AcoxI) and the 
detoxification of ROS (Cat), were more strongly expressed in the hearts of adult mice 
than newborns. This may reflect the higher stress levels experienced by the adult heart, 
including the abundance of ROS. There was a striking 1000-fold increase in Pex11α 
expression between the newborn and adult hearts. However, due to the lack of specific 
antibodies, it was not possible to detect the PEX11α protein to determine whether this 
difference is also reflected at the protein level. Because Pex11α is a key gene involved 
in peroxisome proliferation (Li, Baumgart, et al., 2002), the high levels of Pex11α 
mRNA are likely to reflect the requirement for rapid peroxisome proliferation to 
increase the number of peroxisomes in the adult heart. 
 
5.3. Part II: HL-1 cells as a model to study peroxisomal function 
5.3.1. The HL-1 cell line is a promising model to study heart peroxisomes  
The HL-1 cardiomyocyte line is derived from the mouse left atrium and can be serially 
passaged while maintaining a differentiated phenotype (Claycomb et al., 1998). Earlier 
results showed that HL-1 mRNA and miRNA expression profiles were comparable to 
those of human and mouse hearts, suggesting HL-1 cardiomyocytes are suitable as a 
model for cardiomyocytes in vivo (Schlesinger et al., 2011). 
HL-1 cells have not previously been used to investigate the function of heart 
peroxisomes so we initially characterized the expression of peroxisome-related genes 
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and the abundance of the corresponding proteins in HL-1 cells, compared to the mouse 
left atrium. Although many peroxisome-related genes were expressed in HL-1 cells, 
expression levels were not always comparable to the mouse left atrium.  
Despite these differences, the cells still represent a good model for the investigation of 
peroxisomal functions in the heart because (1) all common peroxisomal marker genes 
are stably expressed, (2) HL-1 cells are the closest cell line to primary cardiomyocytes 
in terms of morphological phenotype (compared to H9C2 cells), and (3) the cells can 
easily be transfected with plasmids or siRNA for molecular analysis. 
 
5.3.2. HL-1 cells for the analysis of peroxisome dysfunction in vitro 
5.3.2.1. Establishment of transfection conditions for Pex14 knockdown 
After establishing the HL-1 cell line in our laboratory and assessing the expression of 
the main peroxisome-related genes, we used RNA interference (RNAi) to knock down 
Pex14 gene expression and thus determine the effect on cell viability and the 
expression of peroxisomal, mitochondrial and cardiac markers.  
Pex14 is required for peroxisomal biogenesis, and mutations in this gene are 
associated with three known clinical case studies (Huybrechts et al., 2008; 
Komatsuzaki et al., 2015; Shimozawa et al., 2004). Symptoms of PEX14 deficiency 
include severe hypotonia, failure to thrive, psychomotor retardation, liver dysfunction, 
and sensorineural hearing impairment (Komatsuzaki et al., 2015). Biochemical 
analysis indicated elevated levels of VLCFAs and low levels of serum plasmalogens in 
the patients (Komatsuzaki et al., 2015). The loss of Pex14 in HL-1 cells inhibits growth 
and proliferation, mimicking severe Zellweger syndrome phenotypes (Maxwell et al., 
2003). The intracellular role of PEX14 in peroxisomal biogenesis has been studied in 
detail. PEX14 is required as a docking factor in the peroxisomal membrane to allow 
the import of matrix proteins (Neuhaus et al., 2014) and it also serves as a membrane 
anchor for microtubules, and is therefore required for peroxisome motility (Bharti et al., 
2011). Recently, PEX14 was identified as an optimal marker for the characterization 
of peroxisomes in different cell types, tissues and species in morphological studies 
(Grant et al., 2013). 
The rapid growth of HL-1 cells reduces the transfection efficiency, but this can be 
addressed by starting with a low number of cells in the transfection experiments. We 
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found that cell densities of 1.5–2×105 per 9.6 cm2 well gave the best transfection results 
(over 90% mRNA knockdown and protein knockdown). A drawback of using such low 
initial cell numbers was that longer post-transfection culture periods were needed to 
produce a sufficient number of cells for mRNA and protein analysis. However, the 
Pex14 knockdown was stable until at least 6 days post-transfection, so we were able 
to investigate mRNA levels after 48–72 h and protein levels after 6–7 days.  
 
5.3.2.2. Consequences of the loss of Pex14 in HL-1 cells 
The knockdown of Pex14 inhibits cell proliferation and therefore we recovered fewer 
cardiomyocytes after transfection compared to the control sample (transfected with an 
inactive siRNA). The quantity of Cat mRNA was higher in the Pex14 knockdown cells, 
which is also seen in Pex gene knockout models (our unpublished data). Cat 
expression is probably induced to compensate for the higher level of ROS generated 
in cells deficient for Pex14. Unfortunately, because only a few cells were available after 
transfection, it was not possible to measure the abundance of catalase protein or 
catalase enzyme activity directly. However, we speculate that the induction of Cat 
expression results in higher catalase activity in the cytoplasm of Pex14 knockdown 
cells because the enzyme would not be imported into the peroxisome correctly. Gene 
expression studies also revealed the radical downregulation of α-Mhc and a moderate 
upregulation of β-Mhc in the Pex14 knockdown cells. The downregulation of α-Mhc 
expression was previously reported in human hypertrophic hearts (Miyata et al., 2000; 
Reiser et al., 2001). The upregulation of β-Mhc in heart tissue is detrimental because 
it inhibits the contractile function of cardiomyocytes (Sugiura et al., 1992). Therefore, 
we speculate that the Pex14 knockdown, which blocks the import of peroxisomal matrix 
proteins, significantly inhibits the function of peroxisomes in HL-1 cells, with 
consequential effects on fatty acid metabolism and oxidative stress management that 
might cause hypertrophic-like changes and impaired contractile function. 
We also analyzed mitochondrial markers and mitochondrial function in the Pex14 
knockdown cells, given the functional overlap and interaction between these two 
organelles in terms of fatty acid metabolism and oxidative stress management. The 
abundance of the mitochondrial marker SOD2, an enzyme involved in mitochondrial 
ROS scavenging, and the ability of mitochondrial succinate dehydrogenase to reduce 
the tetrazolium dye (MTT assay), were unaffected by the loss of Pex14. These results 
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indicate that mitochondria are not affected by the knockdown of Pex14. However, to 
confirm this hypothesis, it would be necessary to investigate other parameters such as 
mitochondrial membrane potential and morphology.  
 
5.3.3. HL-1 cells to study the induction/repression of peroxisome proliferation in 
vitro 
HL-1 cells have been subjected to various treatments in order to simulate specific 
diseases (Andersen et al., 2009; Cormier-Regard et al., 1998; Nguyen and Claycomb, 
1999; Wondergem et al., 2012). Similarly, we treated HL-1 cells with a PPARβ agonist 
to induce the expression of peroxisome-related genes, confirming that PPARβ agonists 
can induce PPAR expression in mouse cardiomyocytes. The activation of PPARβ by 
GW501516 reduced glucose utilization in skeletal muscle cells by switching 
mitochondrial substrate preference from carbohydrates to lipids (Brunmair et al., 2006). 
However, the effects of PPAR agonists on the heart are controversial. For example, 
the PPARγ agonist rosiglitazone is cardioprotective during ischemia-reperfusion 
(Morrison et al., 2011), but in patients with type 2 diabetes the long-term use of 
rosiglitazone increases the risk of cardiac events (Morrison et al., 2011). These 
controversial results suggest that the administration of PPAR agonists and antagonists 
should be evaluated carefully, allowing the selection of suitable candidates. 
Long-term cardiomyocyte-specific PPARβ/δ deficiency in mice leads to the depression 
of myocardial fatty acid oxidation, bioenergetics, and premature death with lipotoxic 
cardiomyopathy (Wang et al., 2010). PPARβ/δ can also induce myogenesis by 
modulating myostatin activity (Bonala et al., 2012). The treatment of HL-1 cells with 
the PPARβ agonist upregulated Cat and Pex14 expression. PPARα, PPARγ and RXR 
agonists can upregulate Cat mRNA and catalase protein expression in primary rat 
astrocytes (Khoo et al., 2013). However, we observed no change in the level of 
catalase in western blots following the treatment of HL-1 cells with PPARα and PPARγ 
agonists (data not shown). This may reflect the much lower basal Pparα and Pparγ 
expression in HL-1 cells compared to mouse atrial tissue, indicating that this cell line 
might be not suitable for the study of PPARα and PPARγ treatments. Catalase 
overexpression in HL-1 cells has also been established in our laboratory (unpublished 
data), offering a powerful tool to study the beneficial effects of catalase overexpression 
in the future. 
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5.4. Part III: Alterations of peroxisomal markers, cardiac markers and 
function in Pex11α knockout animals  
5.4.1. Pex11α and its function in peroxisome proliferation 
The PEX11 protein family consists of three members: PEX11α, PEX11β and PEX11γ 
(Li, Baumgart, et al., 2002). PEX11 proteins share several common features: they are 
small, very basic, and contain putative transmembrane regions, and are the most 
abundant peroxins in the peroxisomal membrane (Erdmann and Blobel, 1996; 
Tusnády and Simon, 2001). PEX11 proteins are required for peroxisome growth and 
division (Koch et al., 2010; Orth et al., 2007) and are believed to participate in the 
elongation step of peroxisome proliferation. Pex11α and Pex11β knockout models 
have been generated in cooperation with Prof. Baumgart-Vogt to analyze the function 
of the Pex11 genes in vivo (Li, Baumgart, et al., 2002; Li and Gould, 2002).  
Pex11β knockout mice display many of the pathological characteristics of Zellweger 
syndrome and provide an excellent model for the study of peroxisomal dysfunction (Li 
and Gould, 2002). However, constitutive Pex11β knockout mice do not survive long 
after birth, which makes it impossible to study the function of Pex11β in the adult heart. 
In contrast, Pex11α knockout mice have a normal macroscopic phenotype and lifespan, 
making it possible to investigate adult heart functions in these animals. No severe 
peroxisomal proliferation defects were observed in the livers of Pex11α knockout mice 
treated with peroxisome proliferators, but the size of the peroxisomes was abnormal 
(Li, Baumgart, et al., 2002). Furthermore, there were no significant effects on the 
peroxisomal α-oxidation or β-oxidation of fatty acids or ether-lipid synthesis in the 
hepatocytes of these animals. Although the loss of Pex11α did not affect the lifespan 
and macroscopic phenotype of mice under normal conditions, mice challenged with a 
high-fat diet displayed a higher body weight than wild-type mice, a greater number of 
tubule-interstitial lesions in the kidneys, and elevated levels of liver triglycerides and 
plasma free fatty acids (Weng et al., 2013). Pex11α overexpression also induced 
peroxisome proliferation in cultured mouse and human cells (Koch et al., 2010; Li, 
Baumgart, et al., 2002). Finally, PEX11α is the main factor responsible for peroxisomal 
division in fungi and is required for normal growth, whereas the loss of PEX11β and 
PEX11γ has no effect on fungal growth (Lee et al., 2015).   
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5.4.2. Pex11α knockout mice without an obvious macroscopic phenotype show 
many alterations at the molecular, morphological and functional levels  
Our results showed that both Pex11α and Pparγ are expressed at higher levels in the 
left ventricle than other heart compartments, which suggests that the corresponding 
proteins play a central role in this part of the heart. We also found that Pex11α was 
upregulated after ischemia-reperfusion injury in rat hearts. We therefore investigated 
the effect of the Pex11α knockout on the functionality of the mouse heart.  
We observed a clear Pex11α knockout phenotype at the molecular level despite the 
minimal macroscopic effects. When Pex11α was disrupted the other two members of 
the Pex11 family (Pex11β and Pex11γ) were upregulated, indicating a compensatory 
effect in which the other PEX11 isoforms take over at least a part of the function of 
Pex11α. The overexpression of PEX11β in human cells can induce peroxisomal 
proliferation. Moreover, the three PPAR genes (Pparα, Pparβ and Pparγ) were induced 
in the hearts of the Pex11α knockout mice, with Pparγ expressed at the highest level.  
Endogenous ligands of the PPAR nuclear receptor family include prostaglandins and 
leukotrienes, which are fatty acids and derivatives of lipid metabolism (Huss and Kelly, 
2004; Vanden Heuvel, 2004; Xu et al., 1999). Many of the known PPAR ligands are 
substrates for peroxisomal β-oxidation and cannot be oxidized inside mitochondria 
(Colasante et al., 2015). For this reason, the loss of peroxisomal activity might cause 
either the accumulation of these derivatives (e.g. eicosanoids) or their depletion (e.g. 
PUFAs), triggering the dysregulation of the PPAR system and in turn the energy and 
ROS metabolism of the cell. Our results demonstrated that even a mild peroxisomal 
biogenesis defect as caused by the loss of Pex11α can induce changes in the 
expression of PPARs. We therefore propose that peroxisomes are directly involved in 
the modulation of the intracellular levels of PPAR ligands and act as sensors of cellular 
lipid homeostasis. When this system is perturbed by the inhibition of peroxisomal 
biogenesis or peroxisomal β-oxidation (e.g. by inflammation or aging), or by 
continuously overloading the β-oxidation pathway with LCFAs, lipid homeostasis is 
disrupted, leading to progressive cardiac dysfunction.  
Nppa and Nppc (encoding the cardiac markers ANP and CNP) were downregulated in 
the hearts of Pex11α knockout mice, whereas Nppb (encoding BNP) was induced. 
Because an increase of BNP is clinically related to right-heart failure (Seeger et al., 
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2013), it is also possible that the Pex11α deficiency plays a role in the functional 
maintenance of the right heart.  
Mitochondrial changes have already been observed in various organs of peroxisomal 
disease models (Baumgart et al., 2001). Changes in the mitochondrial respiratory 
chain enzymes induce mitochondrial manganese superoxide dismutase, which 
indirectly suggests an increase in the production of ROS (Baumgart et al., 2001). SOD2 
was upregulated in the hearts of Pex11α knockout mice, possibly indicating an 
increase in ROS levels caused by the peroxisomal defect. Mitochondrial changes were 
also observed in the livers of Pex11α knockout mice, where ring-shaped mitochondria 
surrounded lipid droplets, and mitochondrial proliferation was reported (Li, Baumgart, 
et al., 2002).  
Despite the molecular changes noted above, the physiological function of isolated 
cardiomyocytes (assessed by measuring their cell shorting capacity) revealed no 
differences between the Pex11α knockout and wild-type mice. The reason for this 
observation is unclear, but we speculate that under control conditions the Pex11α 
phenotype is compensated by other PEX11 proteins. Indeed, when we challenged the 
Pex11α knockout heart using an ischemia-reperfusion model, we found that the heart 
tissue from the knockout mice suffered more damage than the control sample. 
Ischemic heart disease is one of the leading causes of morbidity and mortality 
worldwide (Forini et al., 2015). The protection of the ischemic myocardium is highly 
dependent on early reperfusion. However, inappropriate reperfusion also induces 
reperfusion injury which causes more damage to the heart tissue (Kalogeris et al., 
2014). ROS are thought to play a critical role in ischemia-reperfusion injury. If the 
function of peroxisomes is inhibited by the loss of Pex11α activity, then it is likely that 
the defective peroxisomes left in the cardiomyocytes are unable to protect the cells 
from the oxidative stress caused by the ischemia-reperfusion injury. In conclusion, 
cardiac function is compromised by the Pex11α knockout, but the effect is only visible 
when the heart is exposed to stress.  
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5.5. Part IV:  Perspectives 
5.5.1. Catalase as an important protector of heart function 
H2O2, a major ROS responsible for oxidative stress (Halliwell, 1999), is continuously 
generated by several superoxide dismutases, glucose oxidases and monoamine 
oxidases (Baud, 2004). The hydroxyl radicals derived from H2O2 can damage DNA, 
proteins, and membrane lipids (Halliwell et al., 1992). The two most important enzymes 
involved in H2O2 detoxification are glutathione peroxidase and catalase (Baud, 2004; 
Dringen and Hamprecht, 1997). Catalase is localized in the matrix of peroxisomes in 
most mammalian cells (Ballinger et al., 1994; Yokota and Fahimi, 1981; Zaar, 1992). 
In some species (sheep, monkey and guinea pig), catalase is also present in the 
cytosol of hepatocytes (Bulitta et al., 1996; Geerts et al., 1984; Roels, 1976; Roels et 
al., 1982; Yamamoto et al., 1988). In pathological conditions caused by peroxin 
deficiency, the incorrect targeting of catalase has been observed in the hepatocytes of 
patients (Baumgart et al., 2003; Kamei et al., 1993; Terlecky et al., 2006). The 
presence of catalase in the cytoplasm might protect the cells from further damage 
reflecting the metabolic changes caused by peroxisomal deficiency. The protective 
function of peroxisomal catalase in the heart was first reported almost 40 years ago 
(Fahimi et al., 1979).  
There are few studies of peroxisomal catalase in the heart. Previous studies have 
shown that catalase is localized to the peroxisomes of cardiomyocytes (Herzog et al., 
1974; Hicks and Fahimi, 1977; Yokota and Asayama, 1992). Compared to the liver, 
which has the greatest abundance of peroxisomes, catalase activity in the heart is very 
low (Chen et al., 1994; Doroshow et al., 1980). This explains the low resistance of the 
heart to pathological conditions such as ischemia-reperfusion injury (Chen et al., 1994). 
Hearts that overexpress catalase are protected from the toxicity of anticancer drugs 
like doxorubicin, which induce a burst of ROS that can damage cardiomyocytes (Kang 
et al., 1996). Similarly, mouse hearts that overexpress catalase are more resistant to 
ischemia-reperfusion injury (Li et al., 1997). Moreover, endotoxin pretreatment 
increases endogenous myocardial catalase activity and reduces the severity of 
ischemia-reperfusion injury in isolated rat hearts (Brown et al., 1989). Catalase also 
plays a major role in ethanol oxidation (Bradford et al., 1993). The cardiac-specific 
overexpression of catalase in mice rescues ventricular myocytes from ethanol-induced 
cardiac contractile defects (Zhang et al., 2003).  
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Here we found that the treatment of HL-1 cardiomyocytes with ethanol induces the 
expression of the Cat gene, which may protect the cells from ethanol-induced stress 
and damage. The protective mechanism of catalase is unclear. In newborn mice, the 
cardioprotective effects of catalase have been observed following the administration of 
the PPARγ agonist rosiglitazone (Chen et al., 2012). H2O2 significantly inhibited 
sarcomere shortening in newborn ventricular cells, but treatment with rosiglitazone 
induced Cat expression in the heart and restored normal shortening behavior. However, 
the protective effect was eliminated by the application of a PPARγ antagonist or by the 
direct inhibition of catalase (Chen et al., 2012).  
 
5.5.2. Potential modulation of cardiomyocyte functions by peroxisomal calcium 
signaling  
Ca2+ signaling plays a major role in excitation-contraction coupling and the contractile 
output of cardiomyocytes (Fearnley et al., 2011). It is also necessary for the modulation 
of corresponding short-term and long-term muscle cell adaptations (Wanders, 2004). 
The expression of the ventricular calcium-sensing receptor affects the contractile 
parameters of ventricular heart muscle cells and can modify the electromechanical 
coupling of cardiomyocytes (Schreckenberg et al., 2015).  
Peroxisomes are also involved in calcium handling. Calcium blockers such as 
nicardipine, nifedipine and diltiazem suppress the activities of peroxisomal enzymes 
induced by clofibrate in vivo, including the peroxisomal fatty acyl-CoA oxidizing system 
and carnitine acetyltransferase (Watanabe and Suga, 1988). The first study of calcium 
levels in the lumen of peroxisomes reported a concentration of 52±5 nM, compared to 
100 nM in the mitochondria and 1 mM in the endoplasmic reticulum, although the 
accuracy is disputed because the study was not carried out using living cells and the 
purity of isolated peroxisomes could not be proven (Raychaudhury et al., 2006). A later 
study based on living cells reported that peroxisomes contain 20–50 times as much 
Ca2+ as the cytosol, with concentrations up to 100 µM (Lasorsa et al., 2008). 
Interestingly, as Ca2+ levels increase in the cytoplasm, a corresponding increase 
occurs in peroxisomes accompanied by the activation of catalase (Costa et al., 2013). 
The mechanism of calcium transport through the peroxisomal membrane is not 
understood, although the membrane bristles with receptors that are responsible for the 
exchange of metabolic intermediates and ions (Wanders, 2004).  
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The involvement of peroxisomes in calcium handling suggests they could modulate the 
contractile function of cardiomyocytes by regulating calcium storage in the cytosol, and 
may prevent calcium overload in the heart leading to cardiomyocyte insufficiency. 
 
5.5.3. Peroxisomes as markers of maturation and disease indicator 
Our results show that the abundance of peroxisomal markers changes dynamically 
during heart development and is also affected by the disease state, as shown in the 
ischemia-reperfusion model. Pex11α expression increases by 1000-fold during heart 
development but is suppressed by ischemia-reperfusion injury. This gene could 
therefore provide a highly sensitive marker for changes in heart functions. Certain 
peroxisomal markers may be better indicators of such changes than the common 
cardiac markers α-Mhc and β-Mhc. To the best of our knowledge, the results reported 
herein provide the first evidence that peroxisomal markers are suitable indicators of 
cardiac functions. The next step would be to investigate the behavior of such markers 
in patients with diverse cardiac defects. 
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6. Summary 
Peroxisomes are ubiquitous organelles hosting a wide range of essential metabolic 
enzymes involved in lipid metabolism and free radical detoxification. Therefore these 
organelles maintain homeostasis in the intracellular environment and protect against 
disease. The importance of normal peroxisomal function, and the link between 
dysfunction and disease development, is demonstrated by patients with Zellweger 
syndrome and corresponding mouse models. Due to the extremely short lifespan of 
Zellweger patients and the severe neurological phenotype, the cardiac symptoms are 
not reported as the cause of the mortality. However, in less severe peroxisome-related 
diseases, as seen in patients suffering from adult Refsum disease, the heart deficiency 
is clearly manifested. 
In the work described in this thesis, initial data mining confirmed the expression of 
many peroxisomal genes in the heart, and we experimentally confirmed that 
peroxisomal gene expression differed between the heart and liver, with corresponding 
changes in protein abundance and enzyme activity. Furthermore, we found that the 
number of peroxisomes, and the gene and protein expression profiles, differed among 
the four chambers of the heart. The abundance of peroxisomal mRNAs and proteins 
was higher in the ventricles than the atria. Postnatal development and maturation of 
the heart was accompanied by marked changes in the abundance of peroxisomal 
markers, suggesting that such markers could be used to monitor cardiac development 
and maturation and possibly also to diagnose cardiac diseases. Accordingly, following 
ischemia-reperfusion, Pex11α gene expression was suppressed and the abundance 
of PEX14p increased, confirming that these markers are affected by ischemia-
reperfusion injury. 
Using a general Pex11α knockout mouse, we found that the loss of this gene induced 
a clear molecular phenotype involving the dysregulation of peroxisome-related genes 
as well as changes in mitochondrial and endoplasmic reticulum markers in the heart. 
However, no macroscopic phenotype was observed and there were no obvious 
changes in the morphology of cardiomyocytes under normal conditions. Interestingly, 
cardiomyocytes from the hearts of Pex11α knockout mice showed no impairment of 
contractile function under control conditions even though cardiac markers were 
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affected. However, the hearts of Pex11α knockout mice were less resistant to 
ischemia-reperfusion injury, suggesting that Pex11α and peroxisomes have a 
protective role during the ischemia-reperfusion process. 
Finally, we established a knockdown model of peroxisome deficiency in HL-1 cells. 
These cells contain many peroxisomes with an appropriate enzyme composition. The 
knockdown of the peroxisomal biogenesis gene Pex14 by RNAi caused the disruption 
of cardiac markers, the induction of mitochondrial markers and the inhibition of cell 
proliferation. 
In conclusion, the data presented in this thesis demonstrate that the peroxisomal 
compartment is most abundant in the left ventricle and is closely associated with and 
supportive of normal heart functions. When peroxisomes are depleted or deficient in 
cardiomyocytes, there is a severe disruption of cardiomyocyte homeostasis. Protective 
and therapeutic strategies using peroxisome-related genes as targets may therefore 
help to prevent cardiac dysfunction caused, for example, by ischemia reperfusion injury, 
thus maintaining the healthy function of the heart. 
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7. Zusammenfassung 
Peroxisomen sind ubiquitäre Zellorganellen, die ihre Hauptfunktion im Stoffwechsel 
von Lipid und reaktiven Sauerstoffspezies (ROS) ausführen. Peroxisomen spielen eine 
sehr wichtige Rolle in der Erhaltung der Lipidhomöostase innerhalb der Zelle und der 
Verhinderung von Krankheitsprozessen. 
Die Wichtigkeit der normalen peroxisomalen Funktionen und deren wichtige 
Bedeutung bei ihrem Funktionsausfall werden in vielen Zellweger-Syndrom Patienten 
und Mausmodellen deutlich. Da Patienten mit Zellweger-Syndrom eine extrem kurze 
Lebenserwartung haben, wurden kardiologische Symptome der Patienten bisher nicht 
als Todesursache beobachtet und berichtet. Bei leichteren Phenotypen von 
peroxisomalen Erkrankungen, z.B. adulte Refsum-Symdrom-Patienten, sind jedoch 
klare Zeichen der kardialen Dysfunktion deutlich präsent. 
Die am Anfang der Doktorarbeit durchgeführte Datenbanksuche bestätigte bereits die 
Expression vieler peroxisomaler Gene im Herzen von der C57BL/6J-Mäusen. 
Weiterhin, zeigten die Ergebnisse dieser Thesis, dass die peroxisomalen 
Enzymaktivitäten und Expressionen unterschiedlich waren zwischen Herz und Leber, 
und dass die Verteilung und Anzahl der Peroxisomen in Vorhöfen und Herzkammern 
voreinander abweichend waren. In den Herzkammern, war der Gehalt der 
peroxisomalen mRNAs und Proteine deutlich höher als in den Vorhöfen. Die 
postnatale Entwicklung und Reifung des Herzens wurde begleitet von einer deutlichen 
Veränderung der Peroxisomenmarker. In der Tat, könnten somit peroxisomale Gene 
als mögliche Krankheitsmarker geeignet sein. Nach Ischämie-Reperfusion des 
Herzens, wurde eine starke Reduzierung an Pex11α und eine Erhöhung des Pex14 
Gens beobachtet, was darauf hindeutet, dass Peroxisomen in Ischämie-
Reperfusionsschäden involviert sein könnten. 
Mit Hilfe eines Pex11α Gen-Knockout Mausmodells, das von unserer Arbeitsgruppe 
mit-etabliert wurde (Li, et al., 2002), wurde nachgewiesen, dass Pex11α Gendefekt im 
Herzen, nicht nur dramatische Störungen der peroxisomalen Gene verursachen 
konnten, sondern auch zur Veränderungen in Mitochondrien und von 
endoplasmischen Reticulum Markern führen konnten. Trotz des vorhandenen 
deutlichen molekularen Phänotyps, wurden unter normalen Bedingungen jedoch kein 
makroskopischer Phänotyp und keine Änderungen von morphologischen Parametern 
festgestellt. Obwohl die kardialen Marker in Pex11α Knockout Kardiomyozyten 
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verändert waren, wurde das Kontraktionsverhalten der Kardiomyozyten nicht 
beeinflusst. Dagegen, waren die Herzen von Pex11α knockout Mäusen nicht so 
resistent gegen Ischämie-Reperfusionsschäden, was darauf hindeutet, dass 
Peroxisomen und das Pex11α Gen eine wichtige Rolle bei der Protektion der 
Herzfunktion im Rahmen der Ischämie-Reperfusionsschädungsprozesse spielen 
könnten. 
Zusätzlich wurden Zellkulturstudien an HL-1 Kardiomyozyten durchgeführt, die eine 
vergleichbare peroxisomale Gene Expression wie Kardiomyozyten im Mausvorhof 
aufweisen. Weiterhin wurde durch Transfektion von HL-1-Zellen mit Pex14 siRNA ein 
knockdown Modell des Pex14-Gens zur Nachahmung eines Zellweger-Syndroms in 
Zellkultur etabliert. Zu den Pex14-defizierten Zellen konnten eine veränderte kardiale 
Markerexpression, erhöhte mitochondriale Marker sowie eine Hemmung der 
Proliferation der Zellen beobachtet werden. 
In Rahmen der vorgelegte Doktorarbeit konnten folgende Erkenntnisse erzielt werden: 
Peroxisomen sind reichlich in der Linkskammer vorhandeln und unterstützten die 
normale Herzfunktion. Im Fall eines peroxisomales Gendefekts, kommt es zu 
Störungen der Homöostase des Herzens. Die prophylaktische oder therapeutische 
Peroxisominduktion könnte sich deshalb bei Herz-Kreislauf-Erkrankungen, z.B. 
Ischämie-Reperfusionsschäden, positiv auswirken. 
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9. Index of Abbreviations 
3D three-dimensional 
ABCD3, which is also 
PMP70 
ATP-binding cassette sub-family D member 3 
ABCD4, also named as 
PMP69 
ATP binding cassette subfamily D member 4 
Acox1 peroxisomal acyl-coenzyme A oxidase 1 
Acox3 peroxisomal acyl-coenzyme A oxidase 3 
ADH alcohol dehydrogenase 
ALDH2 aldehyde dehydrogenase 2 
ALDP adrenoleukodystrophy protein 
AMACR 2-methylacyl-CoA racemase 
ANOVA analysis of variance 
ANP atrial natriuretic peptide 
ATP adenosine triphosphate 
BLAST basic local alignment search tool 
BNP brain natriuretic peptide 
bp base pair 
BSA bovine serum albumin 
Cat peroxisomal catalase 
CNP C-type natriuretic peptide 
CO2 carbon dioxide 
CoA  coenzyme A 
CPT carnitine palmitoyltransferase 
Ct threshold cycle 
CVDs cardiovascular diseases 
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CYP2E1 cytochrome P450 2E1 
DAB  3,3′-diaminobenzidine 
DBP D-bifunctional protein 
DDBJ DNA Data Bank of Japan 
DEHA di-(2-ethylhexyl)-adipate 
DEHP di-(2-ethylhexyl)-phthalate 
DEPC diethylpyrocarbonate 
DHA docosahexaenoic acid 
DMSO dimethylsulfoxide 
DRP dynamin-related protein 
ECM extracellular matrix 
EDTA ethylene diamine tetraacetic acid 
ENA European Nucleotide Archive 
ER endoplasmic reticulum 
ESTs expressed sequence tags 
FAD flavin adenine dinucleotide 
Fis1 mitochondrial fission protein 1 
G6P glucose 6-phosphate 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GLUTs glucose transporters 
GNPAT glyceronephosphate O-acyltransferase 
GSH glutathione 
GSSG glutathione disulfide 
h hour 
H2O water 
H2O2 hydrogen peroxide 
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HE hematoxylin and eosin 
HMG-CoA reductase  3-hydroxymethyl glutaryl-CoA reductase 
HZ heterozygote 
IF immunofluorescence 
iNOS  inducible nitric oxide synthase 
IP ischemia reperfusion 
IRD infantile Refsum disease 
KO knockout 
LA left atrium 
LV left ventricle 
M marker 
MDVs mitochondria-derived vesicles 
MFP multifunctional protein 1 
MI mitochondria 
min minute 
ml milliliter 
MnSOD mitochondrial superoxide dismutase 
Ms mouse 
MTT methylthiazole tetrazolium 
NADPH nicotinamide adenine dinucleotide phosphate 
(reduced) 
NALD neonatal adrenoleukodystrophy 
NC negative control 
NCBI National Center for Biotechnology Information 
NO nitrogen monoxide 
O2 dioxygen 
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ONOO- peroxynitrite 
P2 postnatal day 2 
PBS phosphate-buffered saline 
PC positive control 
PCI percutaneous coronary intervention 
PFA paraformaldehyde 
Pmp24 peroxisomal membrane protein 4 
PO peroxisome 
PPARs peroxisome proliferator activated receptors 
PPREs peroxisome proliferator hormone response elements 
PTSs peroxisomal targeting sequences 
PUFAs polyunsaturated fatty acids 
RA right atrium 
Rb rabbit 
RC respiratory chain 
RCDP rhizomelic chondrodysplasia punctata 
RGZ rosiglitazone 
ROS reactive oxygen species 
RT-PCR reverse transcription polymerase chain reaction 
RV right ventricle 
RXR retinoid X receptor 
s second 
SD standard deviation 
SDS sodium dodecylsulfate 
SER  smooth endoplasmic reticulum 
TBS Tris-buffered saline 
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TBST Tris-buffered saline with Tween-20 
TEMED tetramethylethylenediamine 
TPM transcripts per million 
Tris trishydroxymethylaminomethane 
VLCFA very-long-chain fatty acids 
WB western blot analysis 
WT wild type 
X-ALD X-linked adrenoleukodystrophy 
ZS Zellweger syndrome 
ZSD Zellweger spectrum disorders 
α-MHC α-myosin heavy chain 
β-MHC β-myosin heavy chain 
µl microliter 
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